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ABSTRACT.
The Tumour Necrosis Factor (TNF) locus lies within the MHC locus on human 
chromosome 6. It encompasses the genes for TNF, Lymphotoxin alpha (LTa) and 
Lymphotoxin Beta (LTp). The location of the locus has intimated a role for TNF in 
the progression of MHC-linked and also malignant diseases. Ten polymorphic sites 
have been detected within the locus (comprising of RFLPs and microsatellites) and 
consequently, disease-associated alleles are now being looked for. Certain alleles 
have been linked to increased levels of TNF expression and these higher levels are 
thought to contribute to the aetiology of disease states. In this study I have 
examined six of the polymorphic sites spanning the TNF locus in 84 unrelated 
breast cancer patients, presenting at a follow-up clinic in Glasgow Royal Infirmary. 
I obtained allelotype and genotype data on each individual and compared the results 
with those previously obtained within our group for two further adenocarcinoma 
populations (gastric, n=45 and colorectal, n=106) and a control population, n=l 15. 
The results show that there is not a defined malignant genotype at the TNF locus, 
but the breast population does differ significantly to the control population in 
allelotype expression at two of the polymorphic sites, the TNFc and TNFa 
microsatellites (p=0.0282 and 0.0023 respectively). The colorectal cancer 
population is significantly different to the controls with regard to allelotype 
expression at the TNFc locus (p=0.0111) and also shows a significantly different 
genotype expression pattern at this site (p=0.0248) (data supplied by group 
member, Hui-Hui Oh). I also found that, in the breast cancer population, there was 
an overexpression of two alleles and a genotype previously demonstrated to be 
associated with high TNF expression; TNFa2, TNFc2 and the TNFB*1, B*2 
genotype at a Nco-1 endonuclease RFLP site. This leads us to suggest that the 
predicted higher levels of TNF in these patients may play a role in the progression 
to the malignant state.
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a .a . Amino acid
B .C -G Bacillus Calmette-Guerin
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DAG Diacylglycerol
ECM Extra Cellular Membrane
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IFN Interferon
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PBLs Peripheral Blood Leukocytes
PBM Cs Peripheral Blood Mononucleocytes
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p l a 2 Phospholipase A2
RFLP Restriction Fragment Length Polymorphism
SDS-PAGE Sodium Dodecyl Sulphate Polyacrylamide Gel 
Electrophoresis
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SLE Systemic Lupus Erythematosis
SSC P Single-Strand Conformational Polymorphism
Tam Tamoxifen
TILs Tumour Infiltrating Lymphocytes
TNF Tumour Necrosis Factor
UT Untranslated
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INTRODUCTION
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In 1893, Dr. W.B. Coley first described the phenomenon of tumour necrosis, 
which he observed in human cancer patients injected with bacterial toxins derived 
from Streptococcus and Serratia. This lead to the initial supposition that the albeit 
short-term regression resulted directly from the "mixed toxin" administration. Years 
later, O'Malley et al (1962) demonstrated that a serum factor which was induced in 
mice by the injection of lipopolysaccharide (LPS) caused haemonhagic necrosis. It 
was not until 1975 however, that Carswell confirmed the presence of this serum 
factor which could mimic the necrotic actions of endotoxin. He was studying 
bacillus Calmette-Guerin (BCG)- infected mice after treatment with LPS from 
E. coli and observed secondary "haemonhagic necrosis" of transplanted tumours. 
His early tests indicated that the factor was probably released from macrophages in 
response to endotoxin. Due to the biological actions observed, he named this factor 
Tumour Necrosis Factor (TNF). This was followed by the isolation of TNF from 
rabbit and human sera (Green et al, 1976; Matthews et alf 1978).
Twenty years on, a vast spectrum of biological activities has now been determined 
for TNF and its two closely related cytokines; Lymphotoxin Alpha (LTa) 
(previously TNFp or LT) and Lymphotoxin Beta (LTp). These three molecules are 
produced by a variety of cell types in response to various insults. Through 
interaction with the "cytokine network" and intracellular signalling via cell-surface 
receptors, their range of activities includes roles in the host defence against 
infection, immunomodulation, anti-tumour actions and an active role in septic shock 
and cachexia.
Discovery.
It was not until 1984, some 10 years after its initial detection, that the gene sequence 
of TNF was established, cloned and the protein product expressed in two 
independant studies in California; Fennica at Genentech and Shirai at the Beckman 
Research Institute. Both groups showed purified TNF to have a relative molecular 
mass of 17,000 by SDS-PAGE, but nearer 40,000 after non-denaturing gel 
filtration, indicating that TNF may occur naturally in a multimeric form. Both also 
demonstrated its ability to induce haemonhagic necrosis of murine tumours in vivo.
Concurrent studies by Beutler et al (1985), were focusing on the metabolic changes 
which occur during chronic infection, including anorexia and suppression of 
lipoprotein lipase. This wasting, termed "Cachexia" was one of the biological 
effects induced by the macrophage-secreted protein cachectin. Beutler isolated the 
hormone from macrophages and on sequencing, reported a homology to TNF so 
strong, that he concluded they were one and the same molecule. This was evidence 
that TNF was capable not only of acting on tumour cells, but could also modulate 
the metabolic activity of normal cells.
10
In the same year, Gray et al (1985) successfully cloned and expressed the cDNA of 
Lymphotoxin (now LTa) in E.coli..They showed it to be a glycoprotein with a 
relative molecular mass of 60,000-70,000 using molecular sieve chromatography, 
whereas the monomer was only 25,000. Its anti-tumour activity was tested in an in 
vivo tumour necrosis assay involving growing methylcholanthrene-induced (Meth- 
A) sarcomas in mice then injecting the tumours directly with Lymphotoxin. The 
extent of tumour necrosis was determined 24 hours postmortem and shown to be 
significantly high, with up to 75% necrosis being observed.
In 1985, human TNF and LT were localised to chromosome 6  between 6p23 and 
6ql2 by Nedwin et al, using Southern blot analysis of human/murine somatic cell 
hybrids. Sequencing revealed that the two genes were at least 30% homologous. 
This fact, along with the apparent close linkage, suggested they were ancestrally 
related.
The precise localisation of the genes was determined in the following year by Spies 
et al (1986). Using Southern blot analysis of various MHC deletion mutants and 
in situ hybridisation, he assigned TNF and LT to between HLA-DR and HLA-A.
It was not until 1993 that the third gene in the TNF locus was identified (Browning 
et al, 1993). They showed that the cell-surface form of the Lymphotoxin molecule 
formed a complex with a 33kD glycoprotein. Goning and sequencing of this 
molecule revealed it to have significant homology to both TNF and LT, although 
more with LT. Furthermore, its genomic location was found to be next to the 
previously mapped TNF-LT locus. To this end it was named LTp to distinguish it 
from LTa.
Cells o f origin and production regulation.
Until 1985, TNF was also known as Macrophage Cytotoxin (MCT) because the 
macrophage was thought to be the only source. Since then, various other cell types 
have been shown to produce TNF and indeed LT. Under normal physiological 
conditions neither TNF nor LT are detectable, but become so in response to various 
stimuli including lipopolysaccharide (LPS), concanavalin A, bacterial proteins, viral
agents, phorbol diesters, Ca2+ ionophores, phytohaemagglutinin and fungi. LPS 
stimulates TNF and LT production from monocytes/macrophages (Aggarwal et al,
1985), mast cells (Young et al, 1987) and brain astrocytes (Chung et al, 1990). 
Haematopoietic cells can be induced to express TNF and LT, but not in response to 
LPS. Functional T cells secrete TNF on stimulation with concanavalin A (English et 
al, 1991) and LT in response to antigenic or mitogenic stimulation (Early et al,
1986). Lymphocytes and natural killer cells can produce TNF in response to the 
crosslinking of the cell-surface antigen CD16 (Anegon et al, 1988).
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Viruses such as Epstein-Barr, herpes simplex and Sendai alter TNF expression in 
PBLs, with the latter inducing TNF mRNA synthesis. (Berent et al, 1986;
Gosselin et al, 1992). The same induced expression is seen with mycobacterial 
proteins (Wallis et al, 1990), malarial parasite antigens (Picot et al, 1990), tumour 
cell membranes and some tumour cell proteins (Hasday et al, 1990; DeMarco et al, 
1992). Many cytokines are involved in the control of TNF and LT expression.
Upregulation is induced by INF-^ y (Beutler et al, 1986), IL-lp (Bethea et al, 1992),
IL-1 (Nedwin et al, 1985), GM-CSF (in concert with INF-yin human monocytes) 
(Hart et al, 1988), platelet activating factor (PAF) (Maier et al, 1992) and TNF 
itself. Cytokines inducing downregulation include IL-4 (Essner et al, 1989) and IL- 
10 (Ralph et al, 1992). Thus TNF plays an integral role in the inflammatory 
response.
Biological Effects.
The ability of TNF and LT to modulate cellular function has been studied closely in 
vivo and in vitro. Their respective individual activities as well as in combination 
with other polypeptides such as INF-y and the interleukins has been examined. In 
general, the main effects are on growth and immunomodulation, but as described 
below, these multifunctional cytokines have diverse effects on different cells and 
tissues.
(a) In vitro studies.
Cell lines can be categorised on the basis of their response to LT and TNF (Goeddel 
et al, 1986); (1) Cytostatic or cytolytic, (2) Unaffected, (3) Growth stimulation. 
TNF was originally described by Carswell (1975) as an anti-tumour agent It has 
subsequently been shown that TNF and LT are cytotoxic to normal cells as well as 
tumour cells (Kawakami et al, 1989). Approximately 40% of described tumour cell 
lines are sensitive to the antiproliferative (cytostatic) or necrotic (cytolytic) actions. 
In some cases, as with the transformed murine fibroblasts, L929, viability can be 
reduced by as much as 50%. Cell lines which are resistant to TNF or LT 
cytotoxicity appear not to differ in the amount of cell surface receptors, or in the 
ability to internalise the cytokines (Sugarman et al, 1985). This suggests the 
resistance to cytokines is due to a defect in the signal transduction pathways 
following receptor-binding. In addition, some TNF-resistant tumour cell lines have 
been shown to secrete small amounts of TNF (Spriggs et al, 1987). This protective 
capacity of low dose TNF results in the induction of protective proteins such as 
manganous superoxide dismutase (MnSOD), the mitochondrial antioxidant enzyme 
that protects from oxygen free radicals (Wong et al, 1992).
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The cytotoxic effects of TNF and LT can be enhanced by other cytokines, anti­
tumour drugs and heat Both TNF and LT synergise with IFN-y to kill tumour cells 
(Lewis et al, 1987; Matsuo et al, 1992). EL-1 also increases the cytotoxicity 
towards some tumour cell lines (Ruggerio et al, 1987), while cytotoxicity can also 
be further enhanced when TNF is administered along with IFN-7 and heat treatment 
(Dubois et al, 1989). The cytotoxic effect of the drug Tamoxifen is increased by 
TNF when given to MCF-7 cells (Matsuo et al, 1992).
As well as inhibiting proliferation, LT and TNF can also have the opposite effect ie. 
to induce growth. This is not limited to normal cells, as growth stimulation has been 
demonstrated on several tumour cell lines including B cell leukaemias (Digel et al, 
1989) and cervical carcinomas (ME-180neo; Lewis et al, 1987). Suggested 
mechanisms for this have been reviewed (Vilcek and Palombella, 1992) and include 
induction of responsiveness to other growth factors and induction of genes 
mediating progression through the cell cycle. In 1985, Sugarman et al 
demonstrated the ability of LT to act as a growth stimulator and a cytotoxic agent 
towards the same cell lines. For example, at low doses of LT, WI38 cells were 
stimulated, whereas at high LT concentrations, given in concert with INF-?, these 
cells sucummed to the cytotoxic effects.
The immunomodulatory roles of TNF and LT have been demonstrated by various in 
vitro studies of their effects on haematopoeitic cells. Both are secreted by activated 
T (Gray et al, 1984; Green et al, 1986) and B (Nedwin et al, 1985; Sung et al, 
1988) cells and act as autocrine growth factors by upregulating cell-surface receptor 
expression and further TNF production. MHO class-I molecule expression is also 
upregulated on T cells (Schewrich et al, 1987), whereas MHC class-II expression is 
unaffected. Both TNF and LT mediate neutrophil activation and increase oxygen 
free radical production (Ozaki et al, 1988). As well as being the major source of 
TNF, macrophages are also activated by i t  The cells secrete cytotoxic molecules 
such as nitrous oxide (NO) and H2O2. The tumoricidal activity of TNF is enhanced
by its ability to induce monocyte chemotaxis and lymphocyte cell adhesion 
molecules on endothelial cells (Bevilacqua et al, 1987). These activities may attract 
phagocytes from the blood to the sites of tumours.
The catabolic actions of TNF and LT stem from their actions on adipose tissue and 
bone. TNF (by its other name cachectin), was identified as the hormone able to 
modulate metabolic activity in adipocytes (Beutler et al, 1985; Torti et al, 1985). 
Lipoprotein lipase and fatty acid synthase are suppressed and glycerol release is 
stimulated. These actions serve to mobilise energy stores in times of acute illness. 
TNF is regarded as a mediator of protein catabolism in muscle cells (Tracey et al,
1986) and also of the decreased transmembrane potential observed in shock (Tracey 
et al, 1986).
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Both TNF and LT alter the properties of endothelial cells. Upregulation of cell 
surface adhesion molecules promotes procoagulant properties and the inflammatory 
state (Wertheimer et al, 1992). This is further induced by the downregulation of 
thrombomodulin and protein C (Nawroth et al, 1986) and endothelin 1, the 
vasoconstrictor is induced in endothelial cells, contributing to organ dysfunction in 
septic shock (Marsden & Brenner, 1992).
TNF and LT have anti-parasitic and anti-bacterial properties, each mediating 
through different cell types. TNF enhances the cytotoxicity of eosinophils for 
schistosomula (Silberstein et al, 1986), whereas LT, in combination with IL-2, 
activates macrophages allowing the killing of Mycobacterium avium organisms.
(b) In vivo activities.
The in vivo effects of TNF and LT are largely dependant on the site of production 
or administration and the amount produced. At low concentrations, they can be 
beneficial to the host by controlling infections by viruses, bacteria and parasites, 
promoting an inflammatory response and also contributing to tumour cytotoxicity. 
However at high doses, tissue injury, organ failure and septic shock are all induced. 
The anti-tumour effect of TNF varies with the site of administration; intratumoral, 
intraperitoneal or intravenous (Spriggs & Yates, 1992).
Chronic TNF exposure has been implicated as a mediator of the wasting state 
cachexia (Beutler & Cerami, 1986). Further to this, Tracey et al, (1990) showed 
that grafting a TNF-producing tumour to the leg of mice caused cachexia, whereas 
grafting 1 million TNF-secreting cells to the brain caused severe anorexia, with a 
25% reduction in body weight observed after 10 days.. TNF and LT induce septic 
shock which can be fatal (For review see Stricter et al, 1993).
A role for both cytokines is also suggested in the pathogenesis of non-infectious 
disorders and autoimmune diseases. Large amounts of LT are produced in rats 
undergoing experimental allergic encephalomyelitis, the animal model for human 
multiple sclerosis (M.S.) (Ellison et al, 1971). Sharief et al (1991) showed an 
association between increased TNF levels and disease progression in patients with 
M.S. Insulin dependant diabetes mellitus (IDDM) may be made worse by LT; LT 
synergises with INF-y to upregulate MHC class II expression on {1-cells in the islets 
of Langerhans, which could contribute to cellular destruction (Pujol-Borrell et al,
1987). There is increasing evidence for the role of TNF in the pathogenesis of other 
autoimmune diseases, namedly rheumatoid arthritis (Saxne et al, 1988), primary 
billiary cirrhosis (Miller et al, 1992) and systemic lupus erythematosis (SLE) 
(Maury et al, 1989).
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The anti-tumour effects of TNF and LT on animal and human tumours have both 
been demonstrated in animal models. Studies in mice have shown that TNF 
augments T cell cytotoxicity (Tomazic et al, 1988), as well as directly causing 
activation of procoagulant activity in tumour endothelium (Gerlach et al, 1989). 
Recombinant human (rh)TNF displays anti-tumour activity against several different 
human tumour types in vivo, including mammary carcinomas, ovarian tumours, 
lung cancer and gastric tumours (Creasy et al, 1986; Sohmura et al, 1986; Manetta 
et al, 1989). Several general observations have arisen from rhTNF studies; (a) 
Intratumoral, high dose administration is most effective, (b) repeated administration 
is necessary for sustained anti-tumour activity, (c) actual hemorrhagic necrosis is 
rare and (d) a relatively high local dose is necessary. In vivo clinical work has been 
carried out, without a large amount of success (see later).
As with the in vitro studies, the anti-tumour response can be enhanced by other
cytokines. TNF plus INF-y show synergistic effects against rat and human ovarian
tumour xenografts in nude mice (Manetta et al, 1989). Intravenous administration of 
TNF with IL-2 was shown by Winkelhake et al (1987) to inhibit growth of 
subcutaneous murine tumours. Synergy has also been demonstrated with IL-6  
against pulmonary metastatic fibrosarcoma tumours (Mule et al, 1990) and IL-1 
against pulmonary metastases of Lewis lung carcinoma (Ohkwra et al, 1990). TNF 
also augments the anti-tumour actions of irradiation (Leonard et al, 1992) and 
cytotoxic drugs such as adriamycin (Maruo et al, 1992).
The yenes and their gene products.
In 1985, Nedwin et al localised the TNF and LTa (TNFfJ) genes to chromosome 6 . 
Southern blot analysis of DNA from human-murine somatic cell hybrids was 
carried out with cDNA probes. Further analysis of hybrids containing only 
fragments of human chromosome 6  localised it more precisely to between 6p23 and 
6ql2. A year later, Spies et al mapped them within the chromosomal segment 
between HLA-DR and HLA-A, within the MHC locus. A panel of MHC deletion 
mutants was investigated by genomic blot hybridisation and the results corroborated 
by in situ examination of metaphase chromosomes to a TNF cDNA probe. This 
result was confirmed and refined by Dunham et al in 1987. Using pulsed-field gel 
electrophoresis and 'cosmid walking1, they established a map of the entire MHC 
locus, mapping TNF to approximately 250kb centromeric to the MHC class I 
genes.
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Mature LT is made up of three 171 residue monomer units (Gray et al, 1984). His 
sequencing of the cDNA revealed a 14S transcript, l,329bp in length with 79bp of 
5' untranslated (UT) sequence and 626bp of 3' UT sequence. He also showed the 
presence of an additional polyadenylation sequence (AATAAA) upstream of the 
conventional poly(A) tail. Recombinant LT, purified on a mAh (LT-B) column 
generated a product with a relative molecular mass of 18K. A further species was 
also detected at 25K, made heavier due to N-linked glycosyladon.
Pennica et al (1984) were the first to obtain the cDNA sequence of TNF and predict 
from this, the amino acid sequence. TNF was purified from PMA-stimulated HL60 
cells. SDS-PAGE revealed a 17kDa protein. The cDNA was an 18S transcript of 
approximately l,300bp;125 nucleotides (nt) 5TJT, followed by a Methionine 
residue and an open reading frame of 233 amino acids. The context of this Met 
AUG codon conformed to a consensus sequence for eukaryote initiator sites 
[CCA/GCCAUGG]. Following the termination codon, were 792nt of 3UT 
sequence. A long hydrophobic pre-sequence of 76 residues was also predicted.
Pennica compared the amino acid sequence of TNF with that of LT and showed the 
two molecules displayed 28% residue homology. Furthermore, many of the 
differences resulted from conservative amino acid changes [FIGURE 1].
At this time, another group (Shirai et a l, 1984) successfully cloned the TNF gene 
and expressed it in E.coli. Their results were consistent with those of Pennica et al, 
in that SDS-PAGE yielded a 17kDa protein and the deduced amino acid sequence 
was also in agreement Gel filtration under non-denaturing conditions revealed a 
45kDa protein, suggesting that the active TNF molecule exists as a trimer.
A year lata* in 1985, Nedwin et al gained a more detailed insight to the structure of 
both the TNF and LTa genes. They were isolated from a human genomic DNA-1 
library then sequenced by the di-deoxy chain termination method. The LTa primary 
transcript contained three introns ( Intron 1, at 287bp in length was inserted 9bp 
before the coding sequence. Intron 2, at 86bp in length was inserted one residue 
before the mature sequence and intron 3, at 247bp interrupts the 35th codon of the 
mature protein). The 5' UT region was shown to comprise 170 bases. Similarly to 
LTa, TNF was revealed to comprise of three introns, but only the third was in a 
homologous position to LTa. The 5'UT region was 180nt The last exon, encoding 
80% of the secreted LTa, and 89% of TNF showed the greatest homology 
(35%).The LTp gene was not characterised until 1993, by Browning et al. Southern 
blot analysis confirmed its presence in the genome as a single copy gene. It was 
shown to be contained within 4 exons, in an arrangement similar to LTa and TNF, 
but being oriented in the opposite direction [FIGURE 2].
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FIGURE 1. Comparison of the amino acid 
sequence of human TNF with human LTa.
TNF
LTA leu pro gly val gly leu thr pro ser ala ala gin thr ala
TNF val arg ser ser ser arg thr pro ser asp
LTA arg gin his pro lys met his leu ala his ser thr leu
lys
lys
TNF prc va ala his
LTA pro ale ala his
val val ala asn 
leu ile gly asp
pro
3ro
gin ala glu gly gin 
ser lys gin asn ser
gly val glu
leu asn arg arg alaasn 
arg ala asn thr asp arg
ala leu 13U ula asn
ala phe eu gin asp
lei arg asp 
glyjphesef leu ser asn
asn
asn
3ln
ser
leu
leu
val proi ;er glu
hr serval pro
TNF gly leu tyr leu ile tyr ser gin va lei
LTA giy ile tyr Dheval tyr ser gin va va
phe
phe
lys gly { In gly
sei gly fs ala
TNF cys pro ser thr his val leu leu thr his thr ile ser arg ile
LTa tyr ser pro lys ala thr ser ser pro leu tyr leu ala his glu
TNF ala val ser tyr gin thr lys val asn leu leu ser ala ile lys
LTa val gin leu phe ser sergln tyr pro phehis val proleu leu
TNF
LTa
TNF
LTa
ser
sei
pro cys gin arg glu th pro
ser gin lys met val tyr pro
glu gly ala
gly leu gin glu
glu ala lys
protrp 
pro trp
tyr glu pro iloty
leuhis metse
TNF lysltjly asp arg
LTa gin gly asp gin
'ty
leu gly jly val 3he gin leu
hii i gly < ila ala Dhegln leu
3lu
hr
eu ser ala glu ile asn arg pro asp tyr 
leu sei thr his thr asp gly ile pro his
TNF
LTa
leu
leu
asp phe ala glu i ;er 
val leu ser pro her
gly gin val tyr 
th r—  val phe
phe gly
phe gly
TNF ile 
LTa phe
ala leu 
ala leu
The sequences have been aligned so as to show 
maximum homology, by adding two gaps in the LTa 
sequence (— ). Identical amino acids have been boxed.
Adapted from Pennica et al, 1984, Nature 312, p728
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FIGURE 2. Schematic representation of the region of 
human chromosome 6 encompassing TNF. LTa & LTB.
Lymphotoxin p TNF Lymphotoxin a
1.2Kb 2Kb
2Kb
Centromere Telomere
Thick arrows indicate transcriptional orientation. 
Hatched boxes represent translated portions of the 
genes and open boxes indicate untranslated portions.
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The biologically active TNF molecule exists as a homotrimer composed of three 157 
amino acid polypeptide subunits (Eck and Sprang, 1989). X-ray crystallography 
has revealed the structure to be a (5-sandwich comprised of 2 anti-parallel p-sheets 
[FIGURE 3a]. The N-terminus is flexible, whereas the C-terminus is rigid. The N- 
terminus is not necessary for activity. On the other hand, deletions at the C-terminus 
can render the molecule inactive (Creasey et al, 1987).
As with TNF, LT is folded into a p-sheet sandwich (Eck et al, 1992) [FIGURE 3b]. 
Hydrophobic interactions act to stabilise the trimeric structure. The residues 
conserved between LT and TNF are found mainly at the base of the trimer in the
polypeptide loops joining the p-sheets. Results of site-specific mutagenesis of
TNF (Smith et al, 1987) and LTa (Goh et al, 1991) have localised the domains 
involved in receptor interaction to the cleft between subunits near the base of the 
trimer. Indeed, the active sites of TNF were localised to 3 regions clustered at the 
base (Van Ostade et al, 1991). A mutation at one of these sites (Ala 84 to Val) 
abolishes cytotoxicity, while amino acid alterations in close proximity also reduced 
the cytotoxic activity. A mutation at position 91 (Val to Ala) decreased bioactivity, 
suggesting it is important in receptor binding.
The Receptors.
TNF and LT mediate their actions through binding to surface receptors which 
triggers a range of signalling pathways. Two forms of receptor have been identified 
and the cDNAs cloned [FIGURE 4]. The first has a relative molecular mass of 
55kDa and is termed p55 or TNF-R1 (Loetscher et al, 1990). The second has a MW 
of 75kDa and is termed p75 or TNF-R2 (Schall et al, 1990). The p55 gene has 
been mapped to human chromosome 12, whereas p75 maps to human chromosome 
1 (Milatowich et al, 1991). The structure of the receptors is homologous to the 
family of proteins displaying 4 extracellular cysteine-rich domains. This includes 
the nerve growth factor receptor (NGF-R).
The cDNA for the p55 encodes a 455a.a. sequence, comprising a 29a.a. 
hydrophobic leader sequence, a 182a.a. N-terminal extracellular domain, a 2la.a. 
transmembrane domain and a 233a.a. C-terminal intracellular domain. The cDNA of 
p75 encodes a 461a.a. protein containing a 22a.a. signal sequence, a 234a.a. 
extracellular domain, a 28a.a. transmembrane domain and a 176a.a. cytoplasmic 
domain. Most mammalian cells carry both types of receptor, although the ratio of 
p55 to p75 varies, as does the cells’ response to the signals induced by the binding 
of either TNF or LT.
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FIGURE 3. Schematic representations of
(a) TNF monomer and (b) Lymphotoxin 
monomer.
c
Adapted from 
Jones et al, Nature 
338, p227.
(b)
Adapted from Eck 
et al, 1992, J. Biol. 
Chem. 267, p2121.
The beta sheets are represented by the thick arrows and 
the alpha chains by the thin lines.
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FIGURE 4. Domain structure of receptors 
for human tumour necrosis factors.
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X represents the glycosylation sites.
Figures in ( )  represent the number of amino acids in each domain.
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Because the intracellular regions of both receptors show no homology, this 
suggested that they cause the activation of different cell signalling pathways (Lewis 
et al, 1991). There is still conflicting evidence regarding which receptor mediates 
cell proliferation and which is responsible for the induction of cell death or 
apoptosis. Heller et al (1992) showed that human HeLa cells which express mainly 
p55 are not killed by TNF, but if p75 expression is induced by transfection with the 
p75 gene, TNF causes cell death. Contrary to this result, Tartaglia et al (1991), 
using a murine model showed that p55 initiates cytotoxicity and also the induction 
of protective activity (manganese superoxide dismutase) in murine NIH3T3 cells, 
whereas p75 initiates the proliferation of murine thymocytes. These conflicting 
results suggest that the cellular response is dependant upon cell type.
Naturally-occurring soluble fragments of both receptors have been identified in 
human urine and serum (Engelmann et al ,1990; Schutze et al, 1990). They are 
truncated portions of the extracellular domains and could probably act to regulate the 
amount of active TNF and LT in circulation.
Cell Signalling,
On binding to their cell surface receptors, TNF and LT elicit a number of signal 
transduction pathways, mainly involving the activation of protein kinases, with the 
end result of the induction of TNF responsive genes [FIGURE 5]. The receptor 
sequences show that they do not possess any intrinsic protein kinase activity, but 
evidence is growing which suggests that TNF causes the activation of 
phospholipases as its main signalling mechanism.
Phosphatidlycholine-specific phospholipase C (PC-PLC) is activated by TNF 
binding to p55. This causes the production of diacylglycerol (DAG), which in turn, 
is responsible for protein kinase C (PKC) activation (Schutze et al, 1991).
Another phospholipase, PLA2 is activated by TNF in a variety of cells (Wiegman et
al, 1992; Palombella et al, 1989; Neale et al, 1988). As a consequence of this, 
unsaturated fatty acids such as arachidonic acid and lysophosphatidlycholine are 
generated. Both are capable of PKC activation. The actions of cyclooxygenase and 
5-lipoygenase on the two afore mentioned products of PLA2 activation can cause 
prostaglandin (PGE2) and oxygen radicals to be produced, which in turn, lead to 
cellular damage. There is some evidence that pertussis toxin-sensitive GTP-binding 
proteins may couple the TNF receptors to PLA2 (Yanaga et al, 1992; Imamura et
al, 1988).
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FIGURE 5.
Cell Signalling Pathways
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Dressier et al (1992) showed that the activation of sphingomyelinase may be 
involved in TNF-induced signalling. Sphingomyelin is hydrolysed by this enzyme 
to ceramide and sphingosine (Kim et al, 1991). Ceramide stimulates the activation 
of magnesium-dependent protein kinases, including ceramide-activated protein 
kinase, whilst sphingosine as well as causing PKC activation, stimulates both PLA2 
and cyclooxygenase activity (Candela et al, 1992).
Studies involving protein phosphatases (protein kinase inhibitors) have confirmed 
the role of protein kinases in TNF-mediated signalling. Schutze et al (1990) showed 
that PKC activation occurred on TNF administration. Wright et al (1993) 
demonstrated that serine-threonine phosphatase inhibitors such as okadaic acid 
(OKA) and calyculin (CLA) synergistically augmented TNF-induced apoptosis in 
several TNF-sensitive tumour cell lines, including BT-20 mammary carcinoma and 
LNCap prostatic tumour cell lines.
The subsequently activated protein kinases are involved in the activation of the 
nuclear transcription factor NF-kB. This can occur without protein synthesis, so 
that transcription of TNF responsive genes happens rapidly (Hohmann et al, 1990), 
or at the level of induction of the transcription of the NF-kB gene. Other 
transcription factors such as AP-1 (comprising c-fos and c-jun) are also activated by 
TNF (Brenner et a/,1989), but only at the level of gene transcription. Thus, NF-kB 
is the only factor directly activated by TNF. The transcription factors go on to 
induce TNF-responsive genes' (Kronke, 1992).
TNF-responsive genes include transcription factors, growth factors, cytokines and 
cell surface antigens. Some of the primary response genes include a zinc finger 
protein, A20 (Opipari et al, 1992), which has been implicated in protecting cells 
from TNF cytotoxicity. The presence of the zinc finger structure suggests that A20 
is a transcription factor which would control cell-survival through the modulation of 
genes induced in a protein synthesis-dependent response to TNF.
Genetic.FQlym<?n?hisms.
Genetic polymorphism is essential for the function of certain proteins such as the 
MHC class I and class II cell-surface antigens. Studies recently have concentrated 
on the hypothesis that such polymorphic genes may play a role in the pathogenesis 
of HLA- and non-HLA-associated diseases. The TNF locus is the site of multiple 
polymorphic loci; to date, ten have been identified [FIGURE 6]. They are divided 
into three classes; naturally occurring restriction fragment length polymorphisms 
(RFLPs), single strand conformational polymorphisms (SSCPs) and
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FIGURE 6. The polymorphic 
regions of the TNF Locus.
TNFe TNFd TN Fc TNFb TNFa
-238 -308 EcoR-1 AspH-1
Nco-1
Lst-1 LT- beta TNF LT-alpha
TNFe and TNFd lie within intron 2 of Lst-1. -238 & -308 lie 
within the promoter region of TNF. EcoR-1 lies within intron 4 
of LTa. TNFe, AspH-1 & Nco-1 all lie within intron 1 of LTa 
and TNFb and TNFa lie 3.5Kb upstream of LTa.
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microsatellites. Two of the polymorphisms originally identified as SSCPs lie within 
the promoter region of TNF at positions -308 and -238 (Wilson et al, 1993 ;
D'Alfonso et al, 1994) and the three RFLPs are located within the LTa gene 
(Partanen et al, 1988; Webb et al, 1990; Ferencik et al, 1992). The five 
microsatellites (TNFa, b, c, d and e) are scattered along the entire length of the 
locus (Nedospasov et al, 1991; Jongeneel et al, 1991; Udalova et a l , 1993). No 
polymorphic sites have yet been assigned to the LTp gene.
Partanen et al (1988) were the first group to identify a polymorphic region in the 
TNF locus. Using various restriction endonucleases, they located a polymorphic 
EcoRI site in the 3TJT region of LTa exon 4. Two alleles were detected by 
Southern blotting, measuring 2.4kb and 2.5kb. The latter allele was present in only 
4 of the 67 individuals tested. Because the RFLP is so uninformative (the rare allele 
only presenting in 6% of the population), little work has since been carried out on 
it. Partanen also showed a strong association between the rare allele and HLA-B40. 
In 1991, Veijans et al showed an association between the rare 2.5kb allele and 
HLA-Bw60, while demonstrating no association between the EcoRI RFLP and the 
autoimmune disease, anklyosing spondylitis.
Nedospasov et al (1986) identified a polymorphic Nco-1 restriction site by 
comparisons of cloned genomic LTa sequences prior to the exact localisation of the 
TNF genes. Originally this site was wrongly assigned to the TNF gene (Badenhoop 
et al, 1989, Dawkins et al, 1989 and Fugger et al, 1989a & 1989b). It was not until 
two years later that its location within intron 1 of LTa was established by genomic 
Southern blotting using TNF and LTa probes, restriction site mapping of cloned 
genes and direct genomic sequencing (Webb et al, 1990; Abraham et al, 1991; 
Messer et al; 1991; Veijans et al, 1991). Messer et al (1991) showed that the 
polymorphic Nco-1 site is linked to an amino acid substitution in the native protein. 
The amino-terminal asparagine at position 26 is conserved in the rare TNFB* 1 allele 
and threonine in the common TNFB *2 allele. This site is far more informative than 
the EcoRI RFLP, with frequencies of 67% to 71% and 29% to 33% for B*2 and 
B*1 respectively (Fugger et al, 1989 and Messer et al, 1991). Because of this, 
several studies were undertaken to determine whether either of the Nco-1 alleles 
were associated with disease states or differential cytokine production.
Fugger et al (1989a) showed a decreased frequency of the more common B*2 allele 
in patients with primary biliary cirrhosis and in a subsequent paper, reported this 
decrease in four auto-immune diseases, along with a significant increase in the 
frequency of the rare B*1 allele in the patients (Fugger et al, 1989b).
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Regarding differential cytokine production, Sachs et al (1990) reported decreased 
LTa secretion in IDDM patients. In the same year, Jacob et al (1990) stimulated 
monocytes from SLE patients with LPS and showed no association between TNF 
production and either allele, but demonstrated that B*1 homozygotes displayed 
increased LTa production compared to B*2 homozygotes. This was also shown by 
Messer et al (1991) using phytohaemagglutinin (PHA)-stimulated PBMCs. These 
two studies are in direct contrast to that undertaken by Pociot et al (1993) on a
normal population. There appeared to be no difference in LTa secretion by PHA- 
stimulated PBMCs, regardless of Nco-1 allelotype, but LPS-stimulated monocytes 
from B*2 homozygotes displayed increased TNF secretion compared to cells from 
B*1 homozygotes, with heterozygotes displaying intermediate levels. This result is 
surprising considering the Nco-1 site is within the LTa gene. It may be explained 
by the demonstration that a strong positive association exists between B *l, HLA- 
DR3 and HLA-B8 , alleles linked with an MHC-extended haplotype associated with 
immuno-inflammatory diseases. Earlier this year, Derkx et al, (1995) carried out a 
series of experiments which gave results in contrast to the study by Pociot et al 
(1993). They demonstrated that LPS-induced TNF release from PBMNCs was 
greatest in B*l/B*2 heterozygotes, followed by B*1 homozygotes, then B*2 
homozygotes and suggested that the contradictory results were due to differing cell 
populations and stimuli
The next polymorphic region to be defined (by SSCP) was the -308 site (Wilson et 
al, 1992). This lies within the promoter region of the TNF gene and results from a 
G to A transition polymorphism at position -308. Two alleles were detected 
following Nco-1 endonuclease digestion. Allele 1 (Tl) gave two fragments of 87bp 
and 20bp whereas allele 2 (T2) gave a single 107bp fragment The allele frequencies 
in 40 unrelated individuals were 0.84 and 0.16 respectively. The following year, 
the same group using PCR and again SSCP in HLA-typed individuals, showed the 
existance of a strong positive association between the rare T2 allele and the extended 
haplotype HLA-A1, B8 , DR3. As this haplotype is associated with autoimmune 
diseases, the possibility arose of an additional link with the TNF locus. This was 
disputed however by Veijans et al (1994) in relation to ankylosing spondylitis. 
They found no significant differences in allele frequencies between AS patients and 
controls, thus concluding that predisposition to AS is not due to an association 
between TNF alleles and HLA-B27.
In 1994, Wilson et al suggested a possible functional role for the polymorphism. 
Using constructs with the TNF promoter linked to the CAT reporter gene, they 
showed the T2 allele to be associated with higher constitutive and inducible levels of 
TNF transcription than the T l allele. Following this work, McGuire et al (1994) 
demonstrated a role for the polymorphism in the pathogenesis of fatal cerebral 
malaria. The disease severity is increased with higher circulating levels of TNF.
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They showed a higher than expected gene frequency of the T2 allele in the Gambian 
population studied (0.16). This could be because the disadvantage is counter­
balanced by another biological advantage. Heterozygotes may possess optimal TNF 
levels for response to other infections or alternatively the T2 homozygotes are 
protected from fatal conditions other than cerebral malaria.
Also in 1992, a biallelic RFLP was detected within intron 1 of the LTa gene by 
Ferencik et al. The group carried out a systematic analysis of 15 different 
endonucleases using a LTa-specific cDNA probe amongst 74 reference cell lines. 
Only AspH-1 showed a polymorphism resulting from a G to C base change. The 
two alleles detected gave fragments of lOkb and 8+2kb fragments with allele 
frequencies of 0.66 and 0.34 respectively. With regard to allelic associations with 
HLA alleles, the 8+2kb fragments associated with B7 and DR2, whereas the lOkb 
fragment associated with DR1,3, 8  and 9. Using data previously obtained by 
Badenhoop et al (1990), Ferencik etal showed there is no correlation between 
Nco-1 and AspH-1 alleles despite their close proximity. To date, no further work 
has been undertaken on this polymorphism.
The most recently determined polymorphic site was identified in 1994 by D'Alfonso 
and Richiardi, using SSCP. Concentrating on the region containing most of the 
sequences reported critical for TNF gene regulation, a diallelic polymorphism was 
detected at position -238. This site is located within a sequence similar to the 
regulative motif called the Y-box. Detection was based on the influence of sequence 
variation on DNA conformation. A transition of G to A at position -238 altered the 
curvature of the molecule and therefore caused altered electrophoretic retardation. 
127 random individuals were tested; 110 were homozygous for the G allele and 17 
were heterozygous ie. had both the A and G alleles, giving gene frequencies of 0.93 
and 0.07 respectively. The group also considered associations between the two 
-238 alleles and HLA markers and observed that individuals positive for all the 
markers constituting 2 of the well-known Caucasoid extended haplotypes (DQw2) 
and (DQw9) were also positive for the rare A allele. To date, this is the only study 
regarding this polymorphism.
The use of RFLPs as allelic markers is limited due to the small degree of 
polymorphism. For this reason, the technique of microsatellite mapping was 
developed. The repeat number of a dinucleotide repeat (usually CA or CT) is 
measured after PCR amplification and can be used as an allelic marker. Since 1991, 
5 such microsatellite regions have been identified spanning the TNF locus 
(Nedospasov et al, 1991; Jongeneel et al, 1991; Udalova etal, 1993).
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The TNFa and TNFb microsatellites were identified in 1991 (Nedospasov et al ; 
Jongeneel et a l ). They consist of AC/GT and T C / G A  repeat units respectively.
They are located 3.5kb upstream (telomeric) of the LTa gene and have 13 and 7 
alleles respectively. The TNFe microsatellite, also identified by both groups 
consists of a TC/GA repeat unit and is located within intron 1 of the LTa gene; two 
alleles have been identified. The remaining two microsatellites TNFd and TNFe 
were identified in 1993 by Udalova et al.. These linked repeats; TC/GA and 
TC/GA-like respectively, lie 8-10kb downstream of the TNF gene, within intron 2 
of the Lst-1 gene. (No function has yet been ascribed to this gene, which is 
homologous to the murine B144 gene). They consist of 7 and 4 alleles respectively. 
Family studies verified that all the microsatellites are stably inherited and segregate 
as Mendelian alleles.
Three studies have attempted to correlate levels of TNF secretion with microsatellite 
alleles; Turner et al (1993) showed a possible association between TNFd3 and 
TNF level following endotoxin stimulation of monocytes from heart transplant 
recipients. Patients homozygous for d3 had elevated TNF levels compared to d3 
heterozygotes. The group suggest this could be due to an association between the 
TNFd alleles and a transcription regulatory sequence.
Also in 1993, Pociot et al showed that high TNF secretion by monocytes following 
LPS stimulation associated with a2, whereas low secretion correlated with a6 . They 
also showed that monocytes from c2 positive individuals secrete higher levels of 
TNF than monocytes from cl positive individuals and that there are no differences 
between TNFa, TNFb or TNFe in terms of PHA-stimulated LTa secretion from 
PBMCs. Furthermore, differences in TNF secretion were greater when differences 
in DR type were accounted for.
In 1995, Derkx et al showed that endotoxin-induced TNF release from whole 
blood was significantly lower in individuals with a2, a6 or alO than those 
individuals with a4 or al 1. They found no associations in stimulated PBMNCs, 
only the whole blood samples. This may explain the difference to the Pociot study. 
In agreement with this study was the observation that there was no TNFb genotype 
relationship to TNF release upon LPS-stimulation.
Several of the microsatellite alleles form part of extended haplotypes; a2 and b3 
associate with the markers making up the 8.1 ancestral haplotype (Al, B8 , C4AQ0, 
C4B1, DR3) (Abraham et al, 1993). Pociot et al (1993) identified 4 extended 
haplotypes which correlate with TNF secretion levels. They incorporate some of the 
TNFa alleles and are listed below in ascending order of TNF secretion;
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DRw6 , B*l, a4, B40, A2.
DQw8 , DR4, B*l, a6y B44 , A l.
DQw2, DR3, B*l, a2, B8 , Al.
DQw8 , DR4, B*2, a2y B15, A2.
These results fit well with all the work regarding allelic links with TNF secretion, in 
that both the B*1 and a6 alleles had been linked to reduced TNF secretion and B*2 
and a2 with higher secretion levels. This is clearly demonstrated in the context of 
DR4 individuals.
The authors also suggested a direct role for the TNF locus in the pathogenesis of 
IDDM in that patients display a higher frequency of a2 and lower frequency of a6 
than controls and also the DR3/4 IDDM haplotype (DQw8, DR4, C4A3, B*2, a2,
B15) is identical to a higher TNF response.
A large study was undertaken in 1993 by Crouau-Roy et al comparing the TNFa, b 
and c microsatellites in 4 European populations (French, Danes, Basques and 
Greeks) (see discussion for data). Of the 208 possible haplotypes, eight accounted 
for almost 60% of those individuals studied. Each population differed significantly 
in allele frequency and the haplotype data demonstrated the heterogeneity of the 4 
populations, showing it may be useful for discriminating between different ethnic 
groups.
TNFILT and Breast Cancer.
Breast cancer is the second most common cancer to kill women in the Western 
world. As many as 1 in 12 women will develop it at some point during their lives. 
Because of the ambiguous relationship with cancer, TNF expression has been 
extensively studied in populations with this often fatal adenocarcinoma.
The vast majority of studies have shown that TNF expression is increased in the 
cancer populations. Mallmann et al (1991) showed that non-metastatic breast cancer 
patients had serum TNF levels greater than the controls and also that patients with 
progressive disease had the highest levels.
In the following year, Abbate et al (1992) showed that serum TNF and also soluble 
IL-2 receptor levels are increased in breast (and moreso ovarian) cancer patients, 
when compared to controls. However, contrary to the previous study, they also 
demonstrated that the levels were not indicative of disease status.
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In 1994, Miles et al demonstrated that TNF mRNA is expressed more in invasive 
than benign mammary tumours and also that this expression, along with the 
expression of the protein itself is confined mainly to the stroma. They also showed 
that along with increasing tumour grade,was an increase in the number of cells 
expressing TNF.
Several roles for TNF within the tumour microenvironment have been postulated, 
ranging from a direct role in metastasis to the converse role of tumour vascular 
destruction. The process of metastasis is a series of interactions between the cancer 
cell and the environment (see below) leading to tumour cell migration and escape 
from the site of the primary tumour via the lymphatics and/or vasculature and the 
colonisation of lymph nodes or secondary organs respectively.
Metastatic Processes.
1. Transformation of the normal cells.
2. Neovascularisation.
3. Invasion of the extracellular matrix (ECM).
4. Escape into the lymph or vasculature systems.
5. Specific or non-specific arrest of tumour cells in capillary beds of organs.
6 . Extravasation into secondary organs.
7. Proliferation to form metastases.
The ECM is die main barrier against invasion. It comprises a stromal layer and a 
basement membrane. Proteases can be induced by cytokines or indirectly by tumour 
infiltrating lymphocytes (TILs) to degrade this barrier. There are several sources of 
cytokines in and around the site of the tumour, including the tumour cells 
themselves, normal infiltrating host cells and cells in the ECM. They will provide 
the tumour environment with molecules capable of regulating tumour cell 
behaviour. TNF is known to induce the expression of the matrix metalloproteinases 
MMP-2 and MMP-9, which are among the enzymes primarily involved in the 
processes altering the ECM to allow cell migration. In addition, in concert with 
INF-y, TNF alters the proteinase: inhibitor balance leading to the degradation of 
BM proteins underlying the endothelial cells (Stolpen et al, 1986).
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In 1990, Basset et al identified a novel MMP gene, expressed specifically in the 
stromal cells surrounding the invasive breast carcinomas. It was named 
Stromelysin-3 on the basis of its gene sequence. Also in 1990, Monteagudo et al 
investigated the distribution of the MMP type IV collagenase in normal, benign and 
malignant breast tissue. They found an increase of activity in invasive carcinomas of 
the enzyme. Furthermore, in normal tissue activity was confined mainly to 
myoepithelial cells, whereas in malignant tissue there was a redistribution mainly to 
the epithelial cells. They concluded that the enzyme may play a role in tumour 
invasion and metastasis and also that the tumour cells themselves were a souce of 
the enzyme.
From these, and studies like them, it is clear that MMPs are present in the vicinity of 
the tumour, so can be acted upon by TNF to potentiate metastasis. A more direct 
role for TNF in metastasis comes from work by Malik et al (1989). In studies on 
ovarian cancer, they showed that TNF therapy promoted invasion and solid tumour 
formation. Further studies by the same group (Malik et al, 1990) showed that 
Chinese hamster ovary cells transfected with TNF exhibited enhanced invasion and 
metastasis in nude mice, further suggesting the promotion of metastasis by TNF.
As well as enhancing invasion and metastasis, TNF has the potential to play the 
opposing role, that of tumour suppression. As described below, several 
mechanisms have been suggested for this role.
TNF is known for its cytostatic and cytotoxic activities both in vitro and in vivo 
against malignant and non-malignant cell types. Indeed, Sgagias et al (1991) 
showed this effect on the growth of the human breast cancer cell line MCF-7. 
Growth inhibition by TNF is also seen in 231-75-1 and BT-20 cell lines (Bellomo et 
al, 1992). Pusztai et al (1993) demonstrated the dose-dependent, reversible
inhibition of pH] thymidine incorporation and cell growth of the human breast cell 
line T47D by TNF. The cytostatic effect occurs at the Gl/S transition and is 
seemingly mediated by a pathway not involving PKA or C or phosphatases PP1 or 
PP2B.
Van haesenbroeck et al (1991) demonstrated that a constitutive production of low 
levels of TNF by neoplastic cells correlated with decreased tumorigenicity and 
reduced invasiveness. Several mechanisms for this result were suggested.
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1. Autocrine production of TNF induces other cytokines such as IL-1 and IL-6 ,
which are involved in immune reactivity modulation.
2. TNF causes the development of T-cell-mediated immunity and in doing so,
enhances antigen presentation by T-lymphocytes.
3. TNF activates macrophage-mediated tumour cell cytotoxicity.
The group further suggested that continuous low-level exposure to local tumour- 
derived TNF doses could have an important role in host-mediated tumour 
suppression in vivo.
Obviously there is a delicate balance to strike regarding the level of TNF wanted in 
the tumour. The positive effects of a low dose could be outweighed by too much 
TNF leading to increased invasiveness. Treatment regimes involving the 
administration of TNF have been attempted, although none too successfully.
In 1992, Budd et al carried out a Phase n  trial with recombinant TNF. It was 
administered intravenously to patients who had been given one round of 
chemotherapy for metastatic disease. The results of the trial were poor, with little or 
no tumour regression seen, suggesting that as a single agent, rTNF is inactive in 
these patients.
Matsou et al (1992) demonstrated an antiproliferative role for recombinant human 
TNF in combination with INF or Tamoxifen (Tam) to the human breast cancer cell 
lines MCF-7 and ZR-75-1. MCF-7 cells show increased sensitivity to TNF than 
INF, but when both agents are given in combination, the cytotoxic effect was 
synergised. ZR-75-1 cells are resistant to TNF but sensitive to INF and when given 
in combination, display an additive cytotoxic effect They also showed that pre­
treatment of both cell lines with INF increased the cytotoxicity of TNF. Finally the 
group gave Tam plus TNF or INF to ZR-75-1 cells. This increased the cytotoxicity 
over giving Tam alone, the suggestion being that INF causes an increase in the 
expression of oestrogen receptors, allowing further action by Tamoxifen.
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AIMS,
The genetic control over TNF and LT expression must be an important factor in 
cases of cancer. The sheer number of polymorphic sites within the locus suggests 
their importance in this control. The fact that two of these lie within the TNF 
promoter (at positions -238 and -308) further fuels the hypothesis. Taking into 
account the already known information linking genotype expression with levels of 
TNF/LT and disease status, several aims were drawn up for this project;
(1) To cany out a thorough allelotype and genotype analysis of the polymorphic 
sites within the TNF locus on human chromosome 6 in a population of 88 
breast cancer patients.
(lb) In doing so, to optimise the reaction conditions for the detection of the alleles 
where necessary at each polymorphic site.
(2) To compare the data obtained with that previously collected within the group for 
a normal population and two further adenocarcinoma groups (gastric and 
colorectal). This would allow die detection of any differences and/or similarities 
between the populations to be noted, with a possible clue as to whether 
genotype expression patterns were a feature of these malignancies.
(3) To look for correlations between clinical data and allelotype or genotype.
(4) To determine whether the breast cancer population shows similarities to other 
malignant populations where certain alleles linked to high TNF production are 
overexpressed.
(5) To draw conclusions as to the role of high TNF in the malignant state.
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MATERIALS AND METHODS.
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1. Patients
This study involved 88 unrelated breast cancer patients attending the follow-up 
clinics of Professor Colin McArdle and Mr. Peter Stanton at Glasgow Royal 
Infirmary.
2. Collection o f blood.
lOmls of peripheral venous blood was collected from each patient into a vacutainer 
containing tri-potassium ethylene diamine tetraacedc acid (K3 EDTA). The tubes
were stored on ice or at 4°C for a maximum of two hours prior to the isolation of 
the peripheral blood leukocytes (PBLs).
3. Isolation o f peripheral blood leucocytes (PBLs).
The peripheral venous blood, collected as above, was divided equally into two 
25ml universal tubes with three volumes of red blood cell (RBC) lysis solution 
(0.83% w/v ammonium chloride, 0.037g/l EDTA, lg/1 potassium hydrogen 
carbonate). The contents were gently mixed then incubated at room temperature for 
15 minutes. The remaining whole cells were collected by centrifugation at 1,400 
rpm for 10 minutes. The supernatant was discarded and the remaining cell pellet 
resuspended in fresh RBC lysis solution. The incubation and centrifugation steps 
were repeated a further twice. If at this stage, the cell pellet was free of red blood 
cell contamination, the cells were resuspended in 500pl of sterile phosphate 
buffered saline (PBS) (0.8% w/v sodium chloride, 0.144% w/v disodium 
hydrogen phosphate, 0 .02% w/v potassium chloride, 0 .02% potassium dihydrogen 
phosphate, pH 7.4). If however the cell pellet showed contamination with red 
blood cells, it was subjected to a further incubation and centrifugation step prior to 
resuspension in PBS. The PBLs were stored at -20°C until required.
4. Isolation o f genomic DNA from human PBLs.
The PBLs were isolated as detailed above and allowed to thaw prior to DNA 
isolation. 500pl of a 0.4M solution of sodiun acetate was added to each 500pl 
aliquot and mixed gently. 150jj1 of a 10% w/v aqueous solution of sodium dodecyl 
sulphate (SDS), 150pl of a 1 mg/ml solution of proteinase-K (Stratagene) and
200pl sterile water were then added. The digestion was incubated at 37°C for 48 
hours. The resultant product was divided equally between two 1.5ml 
microcentrifuge tubes and subjected to phenolrchloroform extraction as follows;
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an equal volume of Tris/EDTA- saturated phenol:chloroform:isoamyl alcohol 
(25:24:1) was added (lOmM Tris-Cl, l.OmM EDTA, pH8.0). The tubes were 
vortexed then centrifuged at 13,500 rpm for 10 minutes. The upper aqueous layer 
(containing the DNA) was removed into another sterile tube. A further equal 
volume of the Tris/EDTA saturated phenolxhloroform was added and the tubes 
centrifuged for 10 minutes. The upper aqueous layer was again removed to a sterile 
tube and an equal volume of chloroform added. Following a further 10 minute 
centrifugation, the upper layer was transferred to a fresh tube. Genomic DNA was 
precipitated by adding a 10th volume of 5M ammonium acetate and 1ml of 100% 
ethanol. The DNA was removed by spooling onto a sealed glass pasteur pipette. It 
was then washed in 70% ethanol and left overnight to resuspend in 500pl sterile 
water.
5. Standardisation of the DNA concentration.
10pl of the resultant DNA solution was then diluted in 990pl of sterile water and the 
absorbances at 260nm and 280nm measures using a spectrophotometer. If the 
260:280nm ratio was >1.5, the DNA was determined pure enough to have the 
concentration calculated. One O.D.260 unit was taken to represent 50pg/ml of
genomic DNA. Each sample was diluted accordingly in sterile water to a final 
concentration of 50pg/ml. Samples with a 260:280 ratio <1.5 were deemed too 
impure to accurately calculate the DNA concentration, so were subjected to further 
phenolxhloroform extraction. 5jd of the DNA was then run out on a 1% agarose 
gel (LE SeaKem) to check its integrity.
6. Determination o f genotype at the LTaNco-1 RFLP locus.
(a) PCR conditions.
Oligonucleotide PCR primers were synthesised according to the published 
sequences (Messer et al, 1991).
5’ Primer: 5 -CCG TGC TTC GTG CTT TGG ACT G -3'
3' Primer: 3’-AGA GCT GGT GGG GAC ATG TCT G -5’
PCR reactions were carried out in 50pl volumes containing 250ng genomic DNA, 
lpM each primer, 1 unit Taq DNA polymerase, 1.5mM MgCl2, lx  PCR buffer IV
(all Advanced Biotechnologies) and 2mM dATP, dGTP, dCTP & dTTP (GIBCO 
BRL). Each tube was overlaid with 50|il paraffin to prevent evaporation during the 
reaction. Amplification was carried out on a Biometra Thermocycler for 40 cycles
(lmin. at 95°C, 1 min. at 64°C, lmin. at 72°C), proceeded by an initial
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denaturation of 95°C for 6 minutes and concluding with a 5 minute extension time 
at 72°C. Prior to further analysis, the PCR products were stored at 4°C.
(b) Nco-1 restriction endonuclease digestion o f PCR products.
The above PCR amplification generates a 750bp fragment which spans the 
polymorphic Nco-1 site. The presence of a threonine residue at position 26 results 
in the sequence recognised by the endonuclease. The 750bp fragment is cleaved to 
give two smaller fragments of 500bp and 250bp. The presence of an asparagine 
residue at the polymorphic site abolishes the cleavage site, thus generating only the 
750bp fragment on endonuclease digestion.
lOpl aliquots of the PCR products were subjected to Nco-1 restriction endonuclease 
digestion in a total volume of 15pl with 5 units of Nco-1 and lx  Nco-1 buffer 4 
(both N.E.B.). The reagents were centrifuged briefly then incubated at 37°C for 2 
hours. The resultant products were analysed on a 2% LE SeaKem agarose gel (see 
below).
(c) Agarose gel electrophoresis of digestion products.
lOpl of digested and lOpl of sham-digested product were electrophoresed in parallel 
on a 2% LE SeaKem agarose gel containing 0.25mg/ml ethidium bromide (EtBr). 
5pl of Orange-G loading buffer was added to each sample. The gel was run in lx 
TAE buffer at 50mA until the bands were clearly resolved. Hae-Hl digested
0X174 was used as a molecular weight marker. (It gives bands of 1353bp,
1087bp, 872bp, 603bp, 310bp, 271bp, 234bp, 194bp, 118bp and 72bp). The 
banding pattern was visualised under transillumination with an ultraviolet (UV) 
light source.
(d) Genotype determination.
(i) TNFB*1 homozygosity was represented by the presence of the 500bp and 
250bp fragments.
(ii) TNFB *2 homozygosity was represented by the presence of the 750bp fragment 
only.
(iii) Heterozygosity ie. (B*1,B*2) was represented by the presence of all three 
bands [FIGURE 20].
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FIGURE 20. Gel showing possible genotypes at the Nco-1 locus.
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This figure shows the three possible genotypes at the Nco-1 locus. 
Lanes 1 and 8  contain the size m arker Hae-III digested 3>X174.
Lanes 2, 4 and 6 contain the undigested PCR product of 750bp. Lane 
3 contains a sample homozygous for the B*2 allele. Lane 5 contains 
a heterozygous sample (B*l, B*2) and lane 7 contains a sample 
homozygous for the B*1 allele.
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7. Determination offenotwe at the AspHl RFLP locus.
(a) PCR conditions.
The primers previously obtained for the above Nco-1 RFLP analysis were used for 
this reaction. PCR reactions were also identical to those described above.
(b) BsiHKA-1 digestion o f the PCR products.
The amplification generates a 750bp fragment which straddles a polymorphic 
AspHl restriction endonuclease site. The presence of the sequence 
G(A/T)GC(A/T)'C generates two fragments of 425bp and 325bp on digestion with 
the endonuclease. A G to C transversion abrogates the site, thus generating a single 
750bp fragment The endonuclease BsiHKA-1 (an isoschizomer of AspH-1) was 
used for the digestions.
lOpl aliquots of the PCR products were digested with BsiHKA-1 in a total reaction 
volume of 15pl in the presence of 5 units of BsiHKA-1, lx  BsiHKA-1 buffer 3 and 
lOOg/ml B.S.A. (all Advanced Biotechnologies). The reagents were centrifuged
and incubated overnight at 60°C, after being overlaid with paraffin. 10pl of the 
digested and lOpl of sham-digested products were analysed in parallel on a 2% LE 
SeaKem agarose gel as detailed above. The products were again visualised under 
UV light
(d) Genotype determination.
(i) Allele 1 homozygosity was represented by the presence of the 425bp and 325bp 
fragments.
(ii) Allele 2 homozygosity was determined by the presence of the 750bp fragment
(iii) Heterozygosity ie. (1,2) was represented by the presence of all three fragments 
[FIGURE 21].
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FIGURE 21. Gel showing the various genotypes at the AspH-1
lo c u s .
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Lanes 1 and 8 contain H ae-III digested 0X174, run  as a molecular 
weight m arker. Lanes 2 and 3 show the (2,2) homozygote (with 
undigested sample in lane 2). Lanes 4 and 5 show a (1,2) 
heterozygote, with lane 4 containing undigested sample. Lanes 6 and 
7 show a (1,1) homozygote, with undigested sample in lane 6.
4 2
8. Determination of genotype at the TNF -308 locus.
(a) PCR conditions.
Oligonucleotide PCR primers were synthesised according to published sequences 
(Wilson et al, 1992). The 5’ primer was designed to incorporate the -308 
polymorphic site into a Nco-1 restriction site. This was created by a single base 
change (underlined).
5’ Primer: 5’-AGG CAA TAG GTT TTG AGG G£C AT-3’
3' Primer: 5 -TCC TCC CTG CTC CGA TTC CG-3'
PCR reactions were carried out in 50pl volumes containing 250ng genomic DNA, 
2mM dATP, dTTP, dCTP & dGTP (GIBCO BRL), lpM each primer, 1.5mM 
MgCl2, lx PCR buffer-IV and 1 unit Taq DNA Polymerase (all Advanced
Biotechnologies). Each tube was overlaid with 50pl paraffin to prevent evaporation. 
Amplification was carried out on a Biometra Thermocycler for 35 cycles (1 min. at 
94°C, 1 min. at 60°C, 1 min. at 72°C), proceeded with an initial cycle (3 mins. at 
94°C, 1 min. at 60°C, 1 min. at 72°C) and concluding with a 5 minute extension 
time at 72°C. Prior to further analysis, the PCR products were stored at 4°C.
(b) Nco-1 restriction endonuclease digestion o f-308 PCR products.
The PCR generates a 107bp fragment which contains a polymorphic Nco-1 
restriction endonuclease site. The presence of the site results, upon digestion in the 
genetration of two fragments of 97bp and 20bp.
lOpl aliquots of the PCR products were subjected to Nco-1 restriction endonuclease 
digestion in a final volume of 15pl, containing 5 units of Nco-1 and lx  Nco-1 
buffer-4 (both N.E.B). After brief centrifugation, the reagents were incubated
overnight at 37°C. The resultant products were analysed on an 8% polyacrylamide 
gel (see below).
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(c) Polyacrlyamide gel electrophoresis (PAGE) of -308 RFLP digestion products.
10|il of digested and lOpl sham-digested products were electrophoresed in parallel 
on a 20cm x 20cm, 8% polyacrylmide gel rig (Bio-Rad), lx TAE was used as
running buffer and Hae-III- digested 0X174 as the molecular weight marker. 5pl
of bromophenol blue/xylene cyanol buffer was added to each sample and 
electrophoresis carried out until the bromophenol blue ran to within 2cm of the end 
of the gel The gel was then stained by submerging in lxTAE containing 0.4mg/ml 
EtBr for 30 minutes. The banding pattern was visualised under transillumination 
with UV light
(d) Genotype determination.
(i) Homozygosity for allele T l was represented by two fragments of 97bp and 
2 0 bp.
(ii) Homozygosity for allele T2 was represented by a single fragment of 107bp.
(iii) Heterozygosity (T1,T2) was represented by the presence of all three fragments 
[Figure 22].
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FIGURE 22. Gel showing various genotypes at the -308 locus.
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In this figure, Hae-HI digestedd>X174 was used as a molecular 
weight m arker. Lanes 1, 3, 5 to 9, 13 and 14 show samples 
homozygous for the T l allele. Lanes 2, 4, 10, 11 and 12 show 
heterozygous samples (T l, T2).
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9. Determination of^enotwe at the five microsatellite loci.
Only three of the previously described microsatellites were examined in the TNF 
locus, those of TNFa, TNFe and TNFe. There were several reasons for this.
Firstly the tandem positioning of TNFb and TNFd with TNFa and TNFe 
respectively, suggesting a redundancy effect of the former two loci. Secondly, we 
were unable to fully optimise the reaction conditions for the TNFb and TNFd 
microsatellites. Thirdly, data already accrued suggested that the main area of interest 
in the locus was at the telomeric end, so it was deemed unnecessary to continue 
working on the TNFd locus.
Initially, each microsatellite region was amplified according to the protocol below 
and the products run out on a 15% non-denaturing polyacrylamide gel. In the latter 
stages of the project, attempts were made to optimise the conditions for each 
individual microsatellite locus (see later).
(a) PCR conditions.
Oligonucleotide PCR primers were synthesised according to published sequences 
(Udalova et al, 1993).
TNFa 5’: 5'-GCC TCT AGA TTT CAT CCA GCC ACA G-3'
TNFa 3’: 5-CCT CTC TCC CCT GCA ACA CAC A-3’
TNFe 5': 5-GGG AGG TCTGTC TTC CGC CG-3'
TNFe 3’: 5’-CGT TCA GGT GGT GTC ATG GG-3’
TNFe 5': 5’-GTG CCT GGT TCT GGA GCC TCT C-3’
TNFe 3': 5’-TGA GAC AGA GGA TAG GAG AGA GAC AG-3’
PCR reactions were carried out in 20pl volumes containing lOOng genomic DNA, 
0.2mM dATP, dGTP, dTTP (Pharmacia), 0.02mM a32P-labelled (Amersham) 
dCTP, lpM each primer, 1.5mM MgCl2, lx PCR buffer-IV and 0.4 units Taq
DNA polymerase (all Advanced Biotechnologies). Each tube was overlaid with 
20pl paraffin to prevent evaporation. Amplification was carried out on a 96 well
Biometra Thermocycler for 40 cycles (25 secs, at 94°C, 60 secs, at 60°C, 60 secs, 
at 74°Q, proceeded with an initial melting time of 10 mins. at 94°C and concluding 
with a final extension time of 10 mins. at 74°C.
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(b) Non-denaturing PAGE of microsatellite PCR products.
3|ol aliquots of the radiolabelled products were electrophoresed on a 15% non­
denaturing polyacrylamide gel [29:1, acrylamide (GIBCO BRL): bisacrylamide 
(Sigma)]. The gel was run on a Base Ace sequencing gel rig (Stratagene) in lxTBE 
buffer. The samples were loaded with a bromophenol blue/ xylene cyanol loading 
buffer and run overnight at 22mA until the bromophenol blue had run off the 
bottom and the xylene cyanol was within 5cm of the end of the gel. (The xylene 
cyanol runs with an apparent molecular weight of approximately 45). The gel was 
then dried on a vacuum dryer (Biorad) for 1 hour and exposed to photographic film 
(Kodak) to produce an autoradiographic image. The alleles at each polymorphic 
locus were determined by measuring their mobility in relation to a labelled ladder 
(see below) and in comparison to the cosmid M31A, which has the known 
genotype a8, b4, c l, d3, e3.
10. Production o f ^ 2P-labelled lObp ladder.
lpl of ladder (GIBCO BRL) was end-labelled with y^ 2P ATP (Amersham) by
incubating with 4pl 5x Exchange reaction buffer (GIBCO BRL), 5pl y^P ATP, lpl
T4 Kinase (GIBCO BRL) and 9pl water for 30 mins. at 37°C followed by 5 mins.
at 55°C. An equal volume of the bromophenol blue/xylele cyanol loading buffer 
was added to the mix.
11. Production of f 2P-labelled lOObp ladder.
lpl of ladder (GIBCO BRL) was end-labelled by incubation with 4pl 5x Exchange 
Reaction Buffer (GIBCO BRL), 5pl y^P ATP, lpl T4 Kinase (GIBCO BRL) and
9pl water for 30 mins. at 37°C followed by 5 mins. at 55°C. An equal volume of 
the bromophenol blue/xylene cyanol loading buffer was added to the mix.
12. Production of f^P-labelled Haelll-digested 0X174 ladder.
2pl ladder (Sigma) was end-labelled by incubation with 4pl 5x Exchange Reaction 
Buffer (GIBCO BRL), 5pl y^P ATP, lpl T4 Kinase (GIBCO BRL) and 8pl water
for 30 mins. at 37°C followed by 5 mins. at 55°C. An equal volume of the 
bromophenol blue/ xylene cyanol loading buffer was added to the mix.
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13. Optimisation of the protocol for determining fenotwe at the TNFa 
microsatellite locus.
As mentioned above, attempts were made to optimise the PCR and gel conditions of 
the individual microsatellites. Various components of each reaction mix were 
titrated to determine the optimum concentrations.
(a) MgCl2 concentration.
This was varied from 0.5mM to 2.0mM in increments of 0.5mM.
(b) Primer concentration.
This was varied from 0.2pM to l.OpM in increments of 0.2jiM.
(c) Reaction volume.
Initially each PCR amplification was carried out in a total volume of 20pl. Each 
was subsequently duplicated in 50pl volumes.
(d) PCR programme.
A touchdown programme of cycling was tried as an alternative to the original 
programme.
(e) Denaturing PAGE versus non-denaturing PAGE.
(f) Source of Taq DNA Polymerase.
Taq was tested from both Advanced Biotechnologies and Primezyme. In the 
latter case, the enzyme was supplied with pre-optimised PCR buffer (1.5mM
MgCl2) and Mg2+-free buffer. Both were tried during the optimisation process.
Genotype determination was tested on a 6%, 8% and a 10% denaturing 
polyacrylamide gel.
The complete optimised protocol is detailed below.
14. Optimised protocol for haplotype determination at the TNFa microsatellite.
(a) PCR conditions.
Oligonucleotide PCR primers were synthesised according to published sequences 
(Nedospasov et al, 1991).
PCR reactions were carried out in 20|jl reaction volumes containing lOOng genomic 
DNA, 0.2mM dATP, dGTP, dTTP and 0.02mM a32P-labelled dCTP, lpM each 
primer, optimised PCR buffer (1.5mM MgC^) & 0.25 units Taq DNA Polymerase 
(both Primezyme). Each tube was overlaid with 20pl paraffin to prevent 
evaporation during the reaction. Amplification was carried out in a 96-well
Biometra Thermocycler for 40 cycles (25 secs, at 94°C, 60 secs, at 60°C, 60 secs.
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at 74°Q , proceeded by an initial melting time of 10 mins. at 94°C and concluding 
with an extension time of 10 mins. at 74°C.
(b) Denaturing PAGE ofTNFa microsatellite PCR products.
3|il aliquots of the radiolabelled products were electrophoresed on a 6% denaturing 
polyacrylamide gel [19:1 acrylamide (GIBCO BRL): bisaciylamide (Sigma)], 
containing 7.65M urea. The gel was run on a Base Ace sequencing rig (Stratagene) 
in lx  TBE. The gel was preheated for 1 hour prior to sample loading by running it
at 75W. The samples were heated to 80°C for 10 mins. in 6pl of a formamide- 
based buffer (1 mg/ml bromophenol blue, 1 mg/ml xylene cyanol, 80% formamide, 
lOmM EDTA pH 8.0) before being loaded directly from ice. Labelled ladders were 
run, along with the cosmid M31A (a8) and cell-line markers T7527 (a6), OLL 
(a6 ), IBW9 (a4) and LZL (a2) (ECACQ, chosen with reference to Udalova et al, 
1993. The gel was run for 2.5 hours at 69W, until the bromophenol blue had run 
off the bottom and the xylene cyanol was within 8cm of the end. On this 6% gel, 
the latter dye front runs at 1 lObp. The gel was then dried for 50 minutes on a 
vacuum drier (Bio-Rad) and exposed to photographic film to produce an 
autoradiographic image.
(c) Genotype determination.
The alleles were called with the aid of the cell line markers and the cosmid M31A. A 
V^ATP- labelled lObp or lOObp ladder was run on each gel as a size marker. This 
was made according to the original protocol, with the exception that a formamide- 
based loading buffer was added to each [FIGURE 23].
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FIGURE 23. Gel showing various genotypes at the TNFa locus.
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This figure shows a typical TNFa gel. Lane 1 contains the labelled 
lOObp ladder, with the lOObp band represented by the dark band. 
Lane 2 contains M31A (8 ,8 ). The remaining lanes contain a selection 
of the breast cancer patient samples, displaying a range of alleles; 
lane 3 (2,10), lane 4 (6,10), lane 5 (7,11), lane 6  (2,7), lane 7 
(2,11), lane 8 (2,2), lane 9 (2,5), lane 10 (6,11), lane 11 (2,6), lane 
12 (9,11), lane 13 (2,6), lane 14 (2,6) and lane 15 (2,11).
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15. Optimised protocol for senotvpe determination at the TNFc microsatellite 
locus.
These optimised conditions were determined by a further member of our research 
group, Mrs. Joyce Eskdale.
(a) PCR Conditions.
Oligonucleotide PCR primers were synthesised according to published sequences 
(Nedospasov et al, 1991).
PCR reactions were carried out in 20pl volumes containing lOOng genomic DNA,
0.2mM dATP, dGTP, dTTP and 0.02mM a32P-labelled dCTP, lpM each primer,
1.5mM MgQ2, lxPCR buffer & 0 .4units Taq DNA polymerase (all Advanced
Biotechnologies). Each tube was overlaid with 20jil paraffin to prevent evaporation 
during the reaction. Amplification was carried out according to the programme used 
for the TNFa microsatellite.
(b) Denaturing PAGE of TNFc microsatellite products.
3pl aliquots of the radiolabelled products were electrophoresed on a 10% denaturing 
polyacrylamide gel (19:1) acrylamide: bisacrylamide, containing 7.65M urea. The 
gel was run on a Base Ace sequencing rig (Stratagene) in lx TBE. The gel was 
preheated for 1 hour prior to loading the samples by running it at 69W. The
samples were heated to 80°C for 10 mins. in 6pl of a formamide-based loading 
buffer prior to loading directly from ice. The gel was run for 3 hours at 69W until 
the bromophenol blue dye front had run off the bottom of the gel and the xylene 
cyanol was within 5cm of the end. The gel was then dried for 90 minutes on a 
vacuum drier (Bio-Rad) and exposed to photographic film to produce an 
autoradiographic image.
(c) Genotype Determination.
A lObp ladder was run on the gel as a size marker, as the two alleles at this locus 
are 97 and 99 base pairs. The cosmid M31A was also run alongside the samples as 
it is known to be homozygous for allele 1 [FIGURE 24].
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FIGURE 24. Gel showing various genotypes at the TNFc locus.
This figure shows a typical TNFc gel. Lane 1 contains the labelled 
lObp ladder, with the dark band representing lOObp. Lane 2 contains 
the cosmid M31A (1,1). Lanes 3, 6 , 9, 11, 16, 18 & 19 contain 
samples which are also (1,1). Lanes 4, 5, 7, 8 , 10, 12, 13 & 14 
contain samples which are (1,2) and lanes 15 & 17 contain samples 
which are (2 ,2 ).
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16. Protocol for %enotwe determination at the TNFe microsatellite locus.
The reaction conditions of this locus were unchanged from the original non­
denaturing protocol stipulated earlier due to an initial lack of success of various 
optimisation steps carried out by another member of the group, Miss Hui-Hui Oh. 
Genotype determination was decided upon by visualisation only [FIGURE 25].
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FIGURE 25. Gel showing various genotypes at the TNFe locus.
This figure demonstrates a typical TNFe gel. The sample in lane I 
shows the alleles (2,3), samples in lanes 2 and 4 are (1,2) and those 
in lanes 3, 5, 6 , 7 and 8  are (2,2).
5 4
RESULTS.
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(a) Methodology
1. Optimisation of the reaction conditions for the microsatellite reactions
In the original protocol employed, there was a large quantity of non-specific 
banding on the gels. This could not be explained soley by slippage error on the part 
of the Taq DNA polymerase, so steps were taken to optimise the conditions of each 
reaction.
The necessity for optimising the PCR and allele assignment of the microsatellite 
reactions was further demonstrated by the striking results demonstrated when the 
88 breast cancer samples underwent amplification to determine their haplotype at the 
biallelic TNFc microsatellite locus under both the original and optimised protocol 
conditions (see materials and methods for details).
Seventy seven of the 88 samples successfully amplified under both sets of 
conditions and the results are summarised in Table 1.
From these results it was obvious that many of the samples had their genotype 
reassigned from the optimised protocol conditions. Indeed, 35 changes were made 
out of the original 77 allele calls [Table 2].
Confirmation of the allele calls was provided by running DNA from the cosmid 
M31A on the gels along with the samples. It is homozygous for allele 1 at the TNFc 
locus.
2. TNFa Optimisation.
The initial protocol used a non-denaturing PAGE system, but it was determined that 
clearer definition of alleles and also far less non-specific banding were seen if a 
denaturing system was employed (the denaturing agent being 7.65M urea). The 
various components of the PCR reaction mix were individually titrated to find 
optimim concentrations. Varying the MgCl2 concentration from 0.5mM to 2.0mM
was shown to effect the clarity of the gel, with 1.5mM being chosen as optimal.
The concentration of primers in each reaction was also titrated from 0.2pM to 
l.OpM and l.OpM deemed optimal. The effect of overall reaction volume on the 
results was tested by duplicating samples on 20pl and 50pl final volumes. The 20pl 
volume was chosen as optimal.To reduce the non-specific binding made by the 
primers, a touchdown PCR amplification programme was tried, but the results 
failed to show much improvement, so the original programme was retained. The 
concentration of acrylamide in the gel was optimised by duplicating samples on 
6%, 8% and 10% gels (containing acrylamide:bisacrylamide at a ratio of 19:1)
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Table 1
N n n - r i e n a f n r i n p  c o n d i t i o n s  ( o r i g i n a l  p r o t o c o l ! .
Genotype
(1,1)
(1,2)
(2 ,2)
No. of samples 
22
27
28
Denaturing conditions (optimised protocol).
Genotype No. of samples
(1 .1 ) 37
(1 .2 ) 30
(2 .2 ) 10
Table 2
Original Conditions Optimised Conditions No.of samples
changed
(1, 1) (1,2) 1
(1, 1) (2,2) 1
(1,2) (1,1) 6
(1 .2 ) (2,2) 4
(2 .2) (1,1) 11
(2 ,2) (1,2 ) 12
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resulting in the 6% gels being used as the allele separation was far clearer. The final 
component of the reaction mix to be optimised was the Taq DNA polymerase. The 
initial protocol used agents from Advanced Biotechnologies. However, it was 
found that using Primezyme Taq and optimised PCR buffer (1.5mM MgC^) from
Biometra gave the clearest results. This result is clearly demonstrated on two 6% 
gels in which the only difference is the source of Taq and PCR buffer. They 
demonstrate the increased clarity of the Primezyme reagents over those from 
Advanced Biotechnologies on which all the alleles are represented by 'doublets', 
which makes allele determination very unreliable [FIGURE 26 a & b].
To aid the allele determination and give a greater range of standards, cell line DNA 
was obtained from 4 lines as well as DNA from cosmid M31 A. All five are 
homozygous at the TNFa locus as previously mentioned;
The cell lines were acquired because cosmids and plasmids are subject to allele 
instability (Marshall et aly 1993). A y^P-labelled lObp ladder was also run on the 
gels as a size indicator [FIGURE 27].
Allelotwe and Genotype data o f 88 Breast Cancer patients at various polymorphic 
loci spanning the TNF locus.
Blood samples from 88 patients attending the follow up breast cancer clinic were 
obtained. Each was subjected to genotype analysis at the 6 polymorphic sites under 
study, following the lengthy optimisation process (see earlier). Occasionally there 
was a failure in the amplification process, but on the whole the PCR reactions were 
successfully carried out
Table 3 shows the complete data obtained for each sample at the various 
polymorphic sites across the TNF locus and figures 7 to 15 show the individual 
breakdown of the data at each site, with allelotype and genotype frequencies. (In 
Table 3, grade refers to the degree of differentiation of the tumour, with 1 being 
most differentiated and 3 being least differentiated. With regard to size, T1 
represents a tumour of <20mm, T2 represents a tumour of 21-50mm and T3 
represents a tumour of >50mm in diameter). In figures 7 to 15, genotype 1 = (1,1), 
genotpye 2 = (1,2) and genotype 3 = (2,2).
Marker TNFa Alleles
M31A
T7527
OLL
IBW9
LZL
(8,8)
(6,6)
(6 ,6 )
(4 ,4)
(2 ,2 )
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FIGURE 26(a). Gels showing the difference between (a) Advanced 
Biotechnologies and (b) Primezyme Taq and PCR buffers when 
amplifying the TNFa locus.
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This gel was run using Taq DNA polymerase and PCR buffer from 
Advanced Biotechnologies. Compared to the results obtained when 
using Primezyme reagents (Fig. 26b), the latter system is far easier 
to use for allele determination. The gel above displays the 'doublet' 
banding pattern. The samples in each lane were selected to cover the 
entire range of alleles at this locus. Lane 1 (1,2), lane 2 (4,9), lane 3
(2,4), lane 4 (6,13), lane 5 (6,11), lane 6  (7,11), lane 7 (2,10), lane 
8  (2,11), lane 9 (1,14), lane 10 (10,13), lane 11 (4,11), lane 12
(2,10) lane 13 (9,11) lane 14 (2,7), lane 15 (2,7), lane 16 (2,6), 
lane 17 (2,5), lane 18 (4,7) and lane 19 (1,2).
5 9
FIGURE 26(b). Gels showing the difference between (a) Advanced 
Biotechnologies and (b) Primezyme Taq and PCR buffers when 
amplifying the TNFa locus.
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This TNFa gel was run with Primezyme Taq DNA polymerase and 
optimised PCR buffer. When compared to the previous gel showing 
the same samples, this is easier to read as the alleles appear as 
single, dark bands, rather than 'doublets'. The samples in each lane 
were again selected to cover the entire range of alleles at this locus. 
Lane 1 contains the lOObp ladder, with the band representing lOObp 
present only. Lanes 2 & 22 contain M31A (8 ,8 ). Lane 3 (1,2), lane 4 
(4,9), lane 5 (2,4), lane 6 (6,13), lane 7 (6,11), lane 8  (7,11), lane 
9 (2,10), lane 10 (2,11), lane 911 (1,14), lane 12 (10,13), lane 13
(4,11), lane 14 (2,10) lane 15 (9,11) lane 16 (2,7), lane 19 (2,7), 
lane 18 (2,6), lane 19 (2,5), lane 20 (4,7) and lane 21 (1,2).
6 0
FIGURE 27. Gel showing the four cell-lines and the cosmid M31A 
used to aid allele determination.
\ d  3  L t S
Lane 1 contains M31A (8 ,8 )* Lane 2 contains the cell-line T7526 
(6 ,6 ). Lane 3 contains the cell-line OLL (6 ,6 ). Lane 4 contains the 
cell-line LZL (4,4) and lane 5 contains the cell-line IBW9 (2,2). The 
remaining lanes contain samples which cover a range of alleles; Lane 
6 (2,7), lane 7 (4,9), lane 8 (2,10), lane 9 (2,6), lanes 10 & 11
(2,4).
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TABLE 3. G e n o t y p e  and clinical data of the 84 Breast Cancer 
n a t l p n t s .
Sample TNFe -308 TNFc AspH-lNco-1 TNFa Node Grade size
90001 2/2 Tl/Tl 1/1 - B*2/B*2 11/12 +ve ? T1
90002 1/2 T1/I2 1/2 2/2 B*l/B*2 1/2 ? ?  ?
90003 2/2 Tl/Tl 1/1 1/1 B*2/B*2 7/10 +ve ? ?
90004 2/2 Tl/Tl 1/2 2/2 B*l/B*2 4/6 -ve 3 T1
90005 2/2 Tl/Tl 1/2 2/2 B*l/B*2 2/6 -ve 7 T2
90006 - Tl/Tl 1/1 1/2 B*l/B*2 6/11 +ve 2 T1
90007 2/2 T1/T2 1/2 1/2 B*l/B*2 - -ve ? ?
90008 2/2 Tl/Tl 1/2 1/2 B*2/B*2 2/7 -ve 7 7
90009 2/2 T1/T2 1/1 1/2 B*l/B*2 2/11 -ve 7 T2
90010 2/2 T1/T2 2/2 2/2 B*2/B*2 2/4 -ve 7 T2
90011 2/2 T1/T2 1/1 1/2 B*l/B*2 2/13 +ve 2 T1
90012 2/2 Tl/Tl 1/1 1/2 B*l/B*2 6/7 +ve 7 7
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Sample
90013
90014
90015
90016
90017
90018
90019
90020
90021
90022
90023
90024
TNFe
1/2
2/2
2/2
2/2
2/3
2/3
1/2
2/2
1/2
2/2
2/2
2/2
-308 TNFc AspH-lNco-1 TNFa Node Grade size
T1/T2 1/2 2/2 B*l/B*2 2/2 ? ? T1
T1/T2 1/1 - B*2/B*2 11/13 -ve 1 T1
T1/T2 1/1 1/2 B*l/B*2 2/7 +ve ? ?
T1/T2 1/1 1/2 B*2/B*2 6/11 ? ? ?
Tl/Tl 1/1 1/2 B*l/B*2 4/7 +ve 3 T2
Tl/Tl 1/1 2/2 B*l/B*2 6/7 +ve 1 T2
T1/T2 1/2 2/2 B*l/B*2 1/2 +ve ? ?
Tl/Tl 1/2 1/2 B*2/B*2 2/11 +ve ? T1
Tl/Tl 2/2 2/2 B*2/B*2 2/4 -ve ? T2
1/1 1/2 B*l/B*2 2/11 -ve 2 T2
T1/T2 2/2 1/2 B*l/B*2 7/7 -ve 3 T3
T2/T2 1/1 1/2 B*l/B*2 3/7 +ve ? ?
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Sample
90025
90026
90027
90028
90029
90030
90032
90033
90034
90035
90036
90037
90038
TNFe
2/2
2/2
2/2
1/2
1/2
2/2
2/2
1/2
2/3
2/3
2/3
1/3
2/2
-308 TNFc 
Tl/Tl 1/1
Tl/Tl 1/1 
T1/T2 1/1 
Tl/Tl 1/2 
T1/T2 1/2 
Tl/Tl 1/1
Tl/Tl 1/1 
Tl/Tl 1/2 
Tl/Tl 1/2 
Tl/Tl 1/2 
T1/T2 1/1 
Tl/Tl 1/2 
Tl/Tl 1/1
AspH-lNco-1 TNFa
1/2 B*l/B*2 5/12
2/2 B*l/B*2 6/6
2/2 B*l/B*2 2/5
1/2 B*2/B*2 2/10
2/2 B*l/B*2 2/2
1/2 B*l/B*2 6/11
1/1 B*2/B*2 7/11
1/2 B*2/B*2 2/10
1/2 B*2/B*2 2/11
1/2 B*2/B*2 1/14
1/2 B*l/B*2 5/10
1/2 B*2/B*2 2/11
1/1 B*2/B*2 6/11
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Node
-ve
-ve
-ve
+ve
-ve
-ve
+ve
+ve
?
+ve
+ve
-ve
+ve
Sample
90039
90040
90041
90043
90044
90045
90046
90047
90048
90049
90050
90051
TNFe
2/3
2/2
1/2
1/2
2/2
2/2
1/1
2/2
2/2
-308 TNFc AspH
T1/T2 1/1 1/2
T1/T2 1/1 1/2
Tl/Tl 1/1 2/2
T1/T2 1/1 1/2
T1/T2 1/2 2/2
Tl/Tl 1/2 1/2
T1/T2 1/1 1/2
Tl/Tl 1/1 1/1
T2/T2 1/1 2/2
T1/T2 1/2 2/2
Tl/Tl 1/1 1/2
Tl/Tl 1/1 1/2
-INco-l TNFa
B*l/B*2 2/7
B*l/B*2
B*l/B*l 2/6
B*l/B*2 4/10
B*l/B*2 1/2
B*2/B*2 2/11
B*l/B*2 2/11
B*2/B*2 7/7
B*l/B*l 2/2
B*l/B*2 2/2
B*l/B*2 6/11
B*l/B*2 6/11
Node
+ve
+ve
-ve
-ve
+ve
-ve
-ve
-ve
-ve
+ve
+ve
+ve
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Sample
90052
90053
90054
90055
90056
90057
90058
90059
90060
90061
90062
90063
90064
90065
TNFe
2/2
2/2
3/3
3/3
3/3
3/3
3/3
3/3
2/3
2/3
-308 TNFc AspH-lNco-1
T1/T2 1/1 1/2 B*l/B*2
Tl/Tl 1/1 1/1 B*2/B*2
T1/T2 1/1 -
Tl/Tl 1/2 2/2 B*l/B*2
T1/T2 1/2 2/2 B*l/B*2
T1/T2 1/1 1/2 B*l/B*2
Tl/Tl 1/2 1/2 B*2/B*2
T l/H  1/2 2/2 B*l/B*2
Tl/Tl 1/1 1/2 B*l/B*2
Tl/Tl 1/1 1/2 B*l/B*2
Tl/Tl 1/2 1/2 B*2/B*2
Tl/Tl 1/2 2/2 B*l/B*2
Tl/Tl 1/2 1/2 B*2/B*2
Tl/Tl 2/2 2/2 B*2/B*2
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TNFa Node Grade size
3/3 -ve ? T1
7/7 +ve ? ?
3/10 +ve ? T1
2/6 +ve 3 T3
2/4 +ve ? T3
2/11 -ve ? T1
7/9 +ve ? T2
2/4 -ve ? T1
6/13 +ve 1 T2
6/11 +ve 3 T3
4/7 +ve ? T2
-ve 1 T1
2/11 -ve 3 T1
2/4 -ve ? T1
Sample
90066
90068
90069
90070
90071
90072
90073
90074
90075
90076
90077
90078
TNFe -308 TNFc AspH-lNco-1
3/3 Tl/Tl 1/1 1/2 B*l/B*2
3/3 Tl/Tl - 1/2 B*l/B*2
3/3 Tl/Tl 2/2 2/2 B*2/B*2
3/3 Tl/Tl 1/1 1/1 B*2/B*2
Tl/Tl 2/2 1/2 B*2/B*2
2/2 Tl/Tl 2/2 1/2 B*2/B*2
1/2 T2/T2 2/2 2/2 B*2/B*2
1/2 - 2/2 2/2 B*2/B*2
2/2 - 1 / 1 2 / 2  B*l/B*l
2/2 T2/T2 1/2 1/2 B*l/B*2
T1/T2 1/2 2/2 B*l/B*l
T2/T2 1/2 1/1 B*2/B*2
TNFa Node Grade size
+ve ? T2
6/10 -ve 2 T1
2/5 -ve ? ?
7/11 -ve ? ?
2/7 -ve 2 T2
2/11 ? ? T2
2/2 -ve ? T2
-ve 1 T1
2/5 -ve 1 T1
6/11 -ve ? ?
2/6 -ve ? T2
9/11 -ve 2 T1
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Sample
90079
90080
90082
90083
90084
90085
90086
90087
90088
TNFe -308 TNFc
T2JT2 2/2 
T1/T2 1/1 
T2/T2 1/2 
T2A2 1/2 
T2/T2 1/1 
T1/T2 - 
T2/T2 1/2 
T1/T2 1/2
AspH-lNco-1 TNFa
1/2 B*l/B*2
2/2 B*l/B*2 2/6
2/2 B*l/B*l 2/6
1/2 B*2/B*2 2/7
1/2 B*2/B*2 2/11
1/1 B*2/B*2 10/13
1/2 B*l/B*2
1/2 B*2/B*2 4/11
2/2 B*l/B*2 1/2
Node
-ve
+ve
?
+ve
?
+ve
-ve
?
-ve
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The TNFe Locus,
In the breast cancer population at this locus, allele e2 is the most commonly 
expressed, with a frequency of 0.66, followed by allele e3 at 0.23 and allele el at 
0.11. These data are significantly different to those obtained by Dr. D. Campbell in 
our group who looked at this locus in 65 control samples, obtaining frequencies of 
0.03,0.75 and 0.22 for alleles 2,3 and 1 respectively (Figure 7).
The protocol employed to obtain allelic data at this locus employed the use of the 
non-denaturing system which as previously shown is very unreliable. Furthermore 
the data are not relevant to the study as there has yet to be evidence produced 
suggesting a link between this locus and the expression of TNF. The locus was 
only looked at briefly as part of an attempt to obtain data spanning the whole TNF 
locus.
The -308 Locus.
The results at this locus show that allele T1 is by far the most commonly expressed 
in both the breast cancer and control populations (frequencies of 0.69 and 0.80 
respectively) (Figure 8). This expression pattern is also, as expected, reflected in 
the genotype expression pattern observed, with the T1 homozygote frequency of 
0.51 comparing with the heterozygote frequency of 0.37 and T2 homozygotes 
making up the remaining 12% of samples in the breast cancer population. In the 
control population, 64% were (T1,T1), 32% were (Tl, T2) and 4% were (T2, T2) 
(Figure 9).
The Nco-1 Locus.
The allelotype expression at this locus shows B*1 at a frequency of 0.33, with B*2 
at 0.67 in the breast cancer population. In the control population the allele 
frequencies are 0.35 and 0.65 respectively (Figure 10). With regard to genotype 
expression, in the breast cancer population only 6% of patients were homozygous 
for B*l, 40% were homozygous for B*2 and the remaining 54% were 
heterozygous. In the control population, 13% were homozygous for B*l, 45% 
were homozygous for allele B*2 and 13% were heterozygous (Figure 11).
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Fi?ure7.
A comparison of allelotype data between the control population (n=l 15) and the
breast cancer population (n=84) at the TNFe microsatellite locus. The two
populations are significantly different
0.8 -i
0.6 -
Allelotype at the TNFe Locus
0.4 -
Froquoncy
0.2 -
□  Control population
Figure 8
A comparison of aUelotype data between the control population (n=l 15) and the
breast cancer population (n=84) at the -308 polymorphic site in the promoter region
of the TNF gene. The two populations do not differ significantly.
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Figure 9
A comparison of the genotype data at the -308 locus between the control (n=l 15)
and breast cancer population (n=84). The two populations do not differ
significantly in genotype expression.
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Figure 10
A comparison of aUelotype data between the control population (n=l 15) and the
breast cancer population (n=84) at the Nco-1 RFLP locus. The two populations are
not significantly different
A U elotype data  at th e  N co-1 lo c u s
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Figure 11
A comparison of the genotype data at the Nco-1 RFLP locus between the control
(n=l 15) and breast cancer population (n=84). The two populations do not differ
significantly in genotype expression.
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Figure 12
A comparison of aUelotype data between the control population (n=l 15) and the 
breast cancer population (n=84) at the AspH-1 RFLP locus. The two populations 
are not significantly different
A lle lo ty p e  data  at th e  AspH -1 lo c u s
Figure 13
A comparison of genotype data between the control population (n=l 15) and the
breast cancer population (n=84) at the AspH-1 RFLP locus. The two populations
are not significantly different
G en otyp e  data at th e  AspH-1 lo c u s
□  Control population
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The AspH-1 Lqqus.
The most commonly expressed allele, in both populations at this biallelic locus is 
allele 2 (frequencies of 0.62 and 0.60). This is not reflected directly in the genotype 
expression pattern, where in both populations the majority of samples are 
heterozygous 55% and 45% in the breast cancer and control populations 
respectively (Figures 12 and 13). The allelotype data are similar to that obtained by 
Ferencik et al (1992) who made the original discovery of the polymorphic site, 
although his group used the technique of Southern Blotting.
The TNFc Locus.
Allele c l is most frequently expressed at this biallelic microsatellite locus, with a 
frequency of 0.67 in the breast cancer and 0.79 in the control populations. With 
regard to genotype expression, the breast cancer population showed 48% of the 
samples to be homozygous for c l, 11% for c2 and the remaining 41% are 
heterozygous. In the control samples, 64% were homozygous for c l, 5% for c2 
and 31% are heterozygous (Figures 14 and 15).
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Figure 14
A comparison of aUelotype data between the control population (n=l 15) and the
breast cancer population (n=84) at the TNFc microsatellite locus. The two
populations are significantly different (chisquare=4.904, p=0.0268).
0 .8-1
A lle lo typ e  data  at th e  TNFc lo c u s
I  Breast cancer population 
□  Control populationFr equency
Al lele
78
Figure 15
A comparison of genotype data between the control population (n=l 15) and the 
breast cancer population (n=84) at the TNFc microsatellite locus. The two 
populations are not significantly different despite the overexpression of genotype 
(2,2) in the breast cancer population (chisquare=5.252, p=0.0724).
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Comparison ofallelotype data at the TNFa locus between the breast cancer 
population and the control population.
The allele frequencies at this locus are shown below, and in figure 16. Allele a2 is 
by far expressed most frequently (0.31), with a l 1 the next most common allele, at 
0.16. Allele a8 is non-existent in this population of breast cancer patients. Of note is 
the presence of an allele 2bp larger than the original 13 alleles determined at this 
locus. Due to its size, it is referred to here as a 14. This was found in only one 
sample where the patient was (1,14). Chi-square analysis revealed that individual 
alleles 2 and 7 differed significantly between populations (p=0.029 and 0.0445 
respectively). The Monte Carlo significance test showed that taken over all the 
alleles, the two populations are significantly different (p=0.023).
Allele frequencies a t the TNFa locus in 84 breast cancer and 115
control sam ples.
Allele B reast C ontrol
1 0 .03 0 .0 1
2 0.31 0 .2 0
3 0 .03 0 .0 2
4 0 .06 0 .09
5 0 .03 0 .06
6 0 .14 0 .18
7 0 .13 0 .08
8 0 .0 0 0 .0 1
9 0 .0 1 0 .0 2
1 0 O.OS 0.09
11 0 .16 0 .18
1 2 0 .0 1 0 .0 1
13 0 .03 0 .0 2
14 0 .006 0 .0 0
8 0
Figure 16
A llele  fr e q u e n c ie s  at th e  TNFa lo c u s
0.3 i
I  Breast cancer population n □  Control population
1 2 3 4 5 6 7 8 9 1 0 1 1 1 2 1 3  14 
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Comparison o f allelotype and venotvne data obtained at the three polymorphic sites 
within intron 1 ofLTabetween the breast cancer population. 2 further 
adenocarcinomas (colorectal and gastric) and a control population.
I thought it would be interesting to examine the relationships between various 
alleles within the TNF locus, looking for linkage between them in the control group 
and various tumour populations. (I would like to thank Hui-Hui Oh, Joyce Eskdale 
and Dr. David Campbell for the provision of the additional data on which I did the 
analysis).
Since three of the polymorphic sites all lie within 157bp of each other within the 
first intron of the LTa gene (the Nco-1 and AspH-1 RFLPs and the TNFc 
microsatellite), it was deemed reasonable to examine whether, in any of the 4 
populations, patterns pertaining to disease-specificity could be observed and to look 
for linkage between alleles at the three sites.
Initially, allelotype expression was determined at the three sites in the malignant 
populations; breast (n=84), colorectal (n=106) and gastric (n=45) to see whether 
any of these populations showed a tendency to over- or under-express either allele 
at the biallelic sites when compared to the control population (n=l 15). This data 
was obtained with the aid of other members of the research group (Dr. D Campbell, 
Miss HH Oh & Mrs. J Eskdale). The results, shown in Tables 4 to 6 , indicate that 
none of the adenocarcenoma populations differ significantly to the control 
population in terms of allelotype expression at the Nco-1 and AspH-1 loci, but the 
breast and colorectal cancer populations differ at the TNFc locus.
Following this, genotype expression data was obtained for each adenocarcenoma 
populations and compared against the control population. At each of the three loci 
there were three possible genotypes; (1,1), (1,2 ) and (2 ,2).
The results indicated that none of the malignant populations differed significantly to 
the controls at the Nco-1 locus (Table 7). At this locus, allele 2 is known to be the 
most commonly expressed. The data obtained here confirms this with the majority 
(44.8%) of the control population expressing genotype (2,2). This pattern was also 
seen in the colorectal population, but not in the gastric or breast cancer populations, 
where genotype (1,2) is more frequently expressed than (2,2). However, taken 
over all three possible genotypes, neither of the latter two populations differ 
significantly to the controls.
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Table 4. Allelotype expression at the Nco-1 locus, expressed as
frequency, with the nos, of alleles ohserved in ( ).
Population
Control
Breast
Gastric
Colorectal
Allele 1 
0.35 (67) 
0.33 (55) 
0.35 (29) 
0.29 (39)
Allele 2 
0.65 (128) 
0.67 (111) 
0.65 (53) 
0.71 (97)
Tabic , S.. Allelottpe...expressiQn-al the AspH-1 locus, expressed . as.
frequency, with the nos, of alleles ohserved in ( ).
Population Allele 1 Allele 2 
Control 0.40 (41) 0.60 (61)
Breast 0.37 (61) 0.63 (101)
Gastric 0.29 (27) 0.71 (53)
Colorectal 0.34 (26) 0.66 (66)
Table 6 . Allelotype expression at the TNFc locus, expressed as 
frequency, with the nos, of alleles ohserved in ( ).
Population Allele .1 Allele 2
Control 0.79 (156) 0.21 (42)
Breast 0.69 (111) 0.31 (51)
Gastric 0.69 (62) 0.31 (28)
Colorectal 0.67 (128) 0.33 (62)
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Table 7. Genntvnes at the Nco-1 locus, expressed as a percentage.
with actual sample nos, are in ( ).
Population (1 ,1 ) (1 ,2 ) (2 ,2 )
Control 13.5 (13) 41.7 (40) 44.8 (43)
Breast 5.8 (5) 54.0 (47) 40.2 (35)
Gastric 7.3 (3) 56.1 (23) 36.6 (15)
Colorectal 5.9 (4) 45.6 (47) 48.5 (33)
Tahle 8 . Genntvnes a t the AsnH-1 locus, expressed as a percentage. 
with actual sample nos, in ( ).
Population ( 1 , 1 ) ( 1 ,2 ) (2 , 2 )
Control 17.6 (9) 45.1 (23) 37.3 (19)
Breast 6 .0 (5) 54.0 (45) 33.8 (27)
Gastric 12.5 (5) 42.5 (17) 45.0 (18)
Colorectal 8.7 (4) 39.1 (18) 52.2 (24)
Table 9. Genotypes at the TNFc locus, expressed as a percentage. 
with actual sample nos, in ( ).
Pnnulation ( 1 , 1 ) ( 1 ,2 ) (2 ,2 )
Control 64.3 (63) 30.6 (30) 5.10 (5)
Breast 49.3 (40) 38.3 (31) 12.4 (1 0 )
Gastric 50.0 (2 1 ) 45.2 (19) 4.80 (2 )
Colorectal 45.3 (43) 44.2 (42) 10.5 (1 0 )
84
At the AspH-1 locus, the control and breast cancer populations most frequently 
expressed genotype (1,2), whereas the gastric and colorectal populations showed 
genotype (2,2) to be most commonly expressed. However, taken over the three 
possible genotypes, none of the cancer populations differed significantly to the 
controls (Table 8).
At the TNFc locus, genotype (1,1) was the most commonly expressed in each of 
the four populations, which was to be expected due to the vast overexpression of 
allele 1 compared to allele 2. Despite the seemingly similar expression pattern 
observed, the colorectal cancer population does in fact differ significantly to the 
controls (chisquare=7.395, p=0.0248). The frequency of genotype (2,2) is greatly 
increased in the colorectal and breast cancer populations, but taken across all three 
possible genotypes, the breast population is not significantly different 
(chisquare=5.252, p=0.0724) (Table 9).
Finally, it was of interest to determine whether, within any of the four populations, 
any of the genotypes at the three loci were significantly linked to those at either of 
the other two loci ie. whether there was any evidence of extended genotypes in any 
of the adenocarcinoma groups. A significant linkage was found which was 
exclusive to the colorectal cancer population, between AspH-1 (2,2) and TNFc
(1,1); p corrected=0.0256. Other significant linkages were found, either exclusive 
to the control population or common to more than one population (Table 10).
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Tahle 10. Significant linkages between Genotypes a t the three 
nolvm ornhic loci (corrected by Bonferoni's factor).
Population Nco-1 AspH-1 TNFc p  value
Colorectal (2 ,2 ) (1 ,1 ) 0 .0256
Control (2 ,2) (2 ,2) 0 .0064
Control (1 ,1 ) (2 ,2) 0 .0024
Control (2 ,2) (1 ,1) 0 .0008
Gastric (2 ,2 ) (1 ,1) 0 .0040
Breast (2 ,2) (1 ,1) 0 .0040
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Comparison ofallelotwe and genotype between node positive and node negative 
breast cancer patients reveals significant differences at both the TNFa and TNFc 
microsatellite loci.
Nodal status is a reflection of the metastatic behaviour of the tumour at the time of 
surgery. It is used to predict the prognostic outcome of the patient, with a positive 
status equating to poor prognosis and a negative status to a good prognosis.
I separated the breast cancer population on the basis of being either node positive 
(N+ve) or node negative (N-ve) and determined allelotype and genotype data for 
each group at the TNFa, TNFc and Nco-1 loci (those linked with TNF levels and 
prognosis) [Tables 12 and 13].
At the Nco-1 locus, neither the allelotype nor genotype differed significantly 
between the two groups (chisquare=0.539, p=0.537 and chisquare=3.531, 
p=0.1711 respectively).
At the TNFc locus, the two populations differed significantly on the basis of 
allelotype (chisquare=5.540, p=0.0186) and genotype (chisquare=6.433, 
p=0.0401). Interestingly, the cl allele was overexpressed in the N+ve group and 
the (2,2) genotype underexpressed in these patients. This was surprising 
considering that it is allele c2 which is linked with increased TNF levels and hence 
poor prognosis.
At the TNFa locus, the two groups differed significantly when the number of a2 
alleles is compared with the number of non-a2 alleles (chisquare=4.814, 
p=0.0282). Again as with the TNFc result, it is somewhat surprising in that a2 is 
underexpressed in the node +ve population and it is this allele which has been 
linked with high TNF expression and poor prognosis. With regard to genotype at 
this locus, a greater percentage of node positive patients do not carry an a2  allele 
compared to the node negative patients (61% versus 36%), making the two 
populations significantly different (chisquare=4.140, p=0.0419).
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Tahle 12. Allelotvne data of node positive and node negative breast cancer 
patients at the TNFa, TNFc and Nco-1 loci.
TNFa locus.
Node status no, of a£ alletes no. of non
Positive 12 52
Negative 25 45
TNFc locus.
Node status allele cl allele c2
Positive 56 14
Negative 46 28
Ncn-1 locus.
Node status allele B*1 allele B*2
Positive 21 47
Negative 30 52
Table 13. Genotype data of node positive and node negative breast cancer patients 
at the TNFa. TNFc and Nco-1 loci.
TNFa locus.
Node status
Positive
Negative
do. of genotypes
with allele a2 .
13
23
no. of eenotvoes 
without allele a2 . 
20 
13
TNFc locus.
Node status (1.11 (1.21 (121
Positive 22 12 1
Negative 16 14 8
Nco-1 locus.
Node..status O i l 1L21 (221
Positive 0 21 13
Negative 4 22 16
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Usefulness of RFLP and m icrosatellite m arkers in studies involving
immunordcYant genes.
Restriction fragment length polymorphisms (RFLPs) were the initial markers used in 
any such studies. The presence or absence of a restriction endonuclease cleavage site 
within a region of DNA gives rise, on digestion with that enzyme, to a possible biallelic 
pattern. The haplotype tends to be inherited in a Mendelian fashion allowing the 
inheritance of genes to be monitored. The main drawback however is the low degree of 
informativity available from a biallelic site. This is where the use of microsatellite 
polymorphisms has revolutionised the field of DNA markers. They involve the 
presence of di- (or less frequently tri-) nucleotide sequences, tandemly arranged and 
each allele defined by the varying number of repetitions of the sequence. Their high 
abundance throughout the genome and high degree of informativity makes them ideal 
candidates for studying allelic variation in genes or loci of interest (in this study, the 
region of interest being the TNF locus).
PCR-hased determ ination of DNA m arkers.
The polymerase chain reaction is a quick, simple method of amplifying a region of 
DNA within which RFLP and/or microsatellite sites lie. The effectiveness of the 
technique is very much dependant upon the optimisation of the reaction conditions, as 
clearly shown in this study where significant differences were demonstrated during the 
optimisation of the conditions for the TNFa and also the TNFc microsatellite reaction 
conditions.
Genotype determ ination at the TNFa microsatellite locus in a norm al 
population as a means of establishing a technique suitable for use on 
fu rther populations.
In order to establish that the technique set up to determine allelotype at the TNFa 
microsatellite locus was indeed suitable, 115 control samples, ie. samples from people 
with no known disease, were obtained from the tissue typing department at Glasgow 
Royal Infirmary and the allele frequencies obtained compared with those from several 
previous studies carried out worldwide over the past 4 years (Table 11).
From this comparison we were happy with the overall similarities between this study 
and the others in terms of allele frequency patterns, so were felt justified to
(a) Transfer the technique to further populations (the breast cancer population in the 
case of this study) and (b) Use the date obtained to draw further conclusions.
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Table 11. Comparison of allele frequency in control populations at the 
TNFa m icrosatellite locus between this study and a further 7 
populations.
TNFa allele This study [ 1 ] [2 ] [3] [4] [5] [6 ] [7]
1 0.01 ND 0.020 0.007 0.116 - 0.031 0.007
2 0 .20 0.11 0.215 0.307 0.250 0.219 0.208 0.320
3 0 .02 ND 0.034 0.033 0.035 0 .0 1 2 0.031 0.033
4 0.09 0.09 0.040 0.113 0.045 0.037 0.042 0 .100
5 0.06 0.04 0.040 0.067 0.036 0 .110 0.031 0.067
6 0.18 0 .22 0.101 0.140 0.071 0.134 0.094 0.140
7 0.08 0.15 0.134 0.033 0.170 0.073 0.125 0.040
8 0.01 ND 0.040 - - - 0.052 -
9 0 .02 0.07 - 0.033 0.027 0.085 - 0.033
1 0 0.09 0.15 0.154 0.087 0.107 0.134 0.104 0.093
1 1 0.18 0.13 0.128 0.160 0.089 0.098 0.187 0.147
1 2 0.01 0 .02 0.074 0.013 - 0 .012 0.073 0.0133
13 0 .02 0 .02 0.013 0.007 0.054 0.085 0.021 0.007
[1] Nedospasov etal, 1991.
[2] Jongeneel etal, 1991: French population.
[3] Pociot et al, 1993: Danish population.
[4] Crouau-Roy eta l, 1993: Basque population.
[5] Crouau-Roy et al, 1993: Greek population.
[6] Crouau-Roy etal, 1993: French population.
[7] Crouau-Roy et al, 1993 : Danish population.
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As further ’quality control’ checks, three samples which had been previously genotyped 
were run on each TNFa microsatellite gel, along with the cosmid M31A and the four 
cell lines. This confirmed that all the samples ran at the same pace relative to several 
standards. An additional ’internal control’ was also employed, involving the use of 
related individuals. The microsatellite alleles are inherited in a Mendelian manner, so by 
following transmission from parents to siblings or observing groups of siblings, the 
reliability of allele calling could be determined. Six family groups were available for 
study (Figure 17).We were unable to obtain three samples (within families 3,5 & 6), 
but despite this, were clearly able to demonstrate that a Mendelian pattern of inheritance 
of the alleles was feasible in each family group.
Where data were unavailable for the TNFa locus, the alleles determined at the other loci 
under examination were considered in the same manner (data shown below TNFa data), 
and it was found that within each family, the alleles determined could all have been 
transmitted in a Mendelian fashion further supporting our allele calling.
A l l e l o t v n e  d a t a  a t  t h e  T N F e  m i c r o s a t e l l i t e  l o c u s  i n  t h e  b r e a s t  c a n c e r  
p o p u l a t i o n  d o e s  d i f f e r  s i g n i f i c a n t l y  t o  t h a t  o b t a i n e d  f o r  a  c o n t r o l  
n o n n l a t i o n .
The TNFe locus, originally identified in 1993 by Udalova et al is a TC/GA-like repeat 
lying 8-10kb downstrean of the TNF gene, within intron 2 of Lst-1 (Holzinger et al, 
1993). Originally thought to be a triallelic locus, the smallest allele being lOlbp, data 
obtained from detailed cell-line typing has concluded the presence of a larger e4 allele 
(present in the cell lines TAB089 and T7527).
Because of the distance away from the TNF locus, no groups have attempted to relate 
allelotype or genotype at the site to TNF/LT synthesis or expression. The reason for 
TNFe typing the bieast cancer population in this study was primarily to produce a more 
comprehensive ’whole-locus’ study. The fact that the reaction conditions were not fully 
optimised was not essential because of the above reasons. Furthermore, with previous 
studies showing that the loci appearing to have linkage with TNF levels lie at the 
telomeric, as opposed to the centromeric, end of the locus, it was felt unnecessary to 
give too much time to this site.
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Figure 17.
Family groups within the control sam ples used  
a s  internal controls for allele determination.
(2 .2)
(1.1)
Family 1 Family 2.
(2.7) (2,2) -4 TN Fa^
(2.2)
(1.1)
Nco-1
-308
6  0  0
(2,10) (1,2) (2,10)
(-,-) (1 ,2) (1,2 )
(1,2) (2 ,2) (1,2)
Family a. Family 4.
(4,6) TNFa
(1.1) Nco-1
(1.1)-308
6 6 6
(failed to (9,10) (9,10)
amplify)
(2,2) (2,2)
(1.1) (1.1)
ITNFa 6
(2,2) "4NC0-1 (^>11) TNFa (6,13) 
(1,1) -4 -308 (1 >2) Nco"1 (1 -2)
(1,2) -308 (1,2)
Family 5. Family 6.o
6 6 6
TNFa (11,13) 
Nco-1 (“.") 
-308 (1,1)
- □
(6 .11) 
(1,1)
O *’ •’ »
(5,7)
(-,-)
(1.1)
(4,6) (no sample left) TNFa (no sample left)
(1.1) (2,2) Nco-1 (2,2)
(1.2) (1,1) -308 (1-1)
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Comparing the data obtained for the breast cancer population with that previously 
obtained by Dr. D. Campbell in the group for a control population suggests that the 
allele expression pattern shown by the cancer population at the TNFe locus could be 
unique. However the absence of optimal reaction conditions meant that there were 
several non-specific bands present on the gel, which caused some ambiguity when the 
alleles were being called. This result therefore was not looked on as important
One of the polymorphic loci not examined in this study, that of the TNFd microsatellite, 
lies linked to the TNFe locus. It too displays a TC/GA repeat sequence, but consists of 
7 alleles, the smallest being 129bp (Holzinger et al, 1993). Data was not obtained for 
this locus for a variety of reasons. Only one previous study (Turner et al, 1993) has 
attempted to correlate allelic variation at this site with TNF levels. The results showed 
only a tenuous link between d3 and increased TNF levels, which was not deamed 
sufficient evidence to look at the site ourselves. Furthermore, as with the TNFa and B 
loci, the TNFd microsatellite lies in close linkage with TNFe, the site at which we had 
already gathered data. Finally the TNFd locus is situated at a distance from the TNF 
gene cluster, certainly far from sites previously linked to TNF expression, so we felt 
justified in omitting it from this study.
The hreast cancer population does not show a unique allele expression 
pattern a t the -308 RFLP. located in the TNF pene prom oter region.
The interest in this locus stemmed from its positioning in the TNF promoter. Had the 
breast cancer population shown a unique expression pattern, it could have been 
postulated that this polymorphism was therefore involved in controlling the level of 
TNF expression and even LT production. Whether this increased or indeed decreased 
the cytokine levels would have been of particular interest as other polymorphic loci have 
shown linkage with increased TNF levels.
The results of the allelotyping however show the common allele (Tl) to be expressed 
with a frequency of 0.69 and allele 2 (T2) with a frequency of 0.31. This is similar to 
the original study by Wilson et al in 1992 where values of 0.84 and 0.16 respectively 
were obtained for his 40 control samples. Furthermore, it is also similar to the results 
obtained by workers in our own research group on a control population of 91 samples 
where frequencies of 0.8 and 0.2  respectively were obtained.
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The second polymorphic site not to be considered in this study lies 70bp downstream 
from the -308 locus, at position -238. This also lies within the promoter region of the 
TNF gene. It was felt that the biallelic site displayed too low an informativity (less than 
7% of the population carry the rarer allele) to be considered for detailed study. 
Nedospasov et al have shown (personal communication) that deletion mutants lacking 
the -238 site do not have altered LPS-induced TNF production, suggesting a lack of 
involvement for this site in the regulation of TNF expression. They have also shown 
that the -238 and -308 loci are in linkage equilibrium with each other, which is 
somewhat unexpected due to their close proximity. This could suggest that they are 
both ancient polymorphic sites.
The third of the polymorphic sites within the TNF locus not to be studied for this 
project is the next polymorphic site upstream of the -308 polymorphism. It is the 
biallelic EcoR-1 RFLP, located in the 3'UT region of LTa exon 4. This site displays 
low informativity (Partanen et al, 1988) and no linkage between either of its alleles and 
TNF levels has been detected, so it was deemed unnecessary to investigate.
Intron 1 of the Lvmphntnxin alnha gene.
With data available on a further 2 adenocarcinoma populations (gastric and colorectal) 
as well as the control population, a more detailed comparison was possible for the three
polymorphic loci located within intron 1 of the LTa gene, namely the TNFc 
microsatellite and the AspH-1 and Nco-1 RFLPs. As well as determining allele 
expression at these loci, we wanted to ascertain whether within each population there 
was a unique pattern of allele expression which may suggest the importance of a 
particular site in the control of expression of TNF in the progression to malignancy. We 
also wanted to determine whether there were significant linkages between alleles at the 
three loci which would suggest if the sites were under a single control factor or are 
independant of each other with regard to the control of TNF expression.
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(a) Allelotvne expression within intron 1 of Lvmnhntoxin a.
With regard to the allelotyping results at each of the three loci, none of the malignant 
populations differed significantly to the control population at both the Nco-1 and 
AspH-1 RFLPs, but both the breast and colorectal cancer populations differed 
significantly to the control population at the TNFc locus (chisquare=4.904, p=0.0268) 
and (chisquaie=6.445, p=O.0111) respectively. Both these populations express allele 2, 
the rarer allele, at a slightly higher frequency than the gastric cancer population. The 
TNFc2 allele has been linked to increased TNF expression, so the results could suggest 
a role for higher TNF levels in the progression to malignancy in breast and colorectal 
cancers.
(hi Genotype expression within intron 1.
Two previous studies (Pociot et al, 1991 & Deikx et al, 1995) showed contradicitng 
results as to genotypic associations at the Nco-1 locus. Using activated monocyte 
cultures, Pociot demonstrated that the B*2 homozygote genotype was linked to high 
TNF production. Derkx on the other hand, using stimulated PBMNCs showed that 
samples with the heterozygous genotype (B*l, B*2) released significantly higher levels 
of TNF than the B*1 homozygotes and moreso than the B*2 homozygotes. With regard 
to the genotype expression patterns determined in our study at the Nco-1 locus, none of 
the malignant populations differed significantly to the control population. The high TNF 
expression genotype as determined by Pociot (B*2,B*2) was only most common in 
one of our malignant populations (colorectal) and also in the controls. As Pociot's data 
was obtained only from activated monocytes, this is less likely to reflect the in vivo 
situation than the data obtained by Derkx from activated PBMNCs. In accordance with 
his results, we have shown that both the breast cancer and gastric cancer populations 
display the heterozygous genotype (B*l, B*2) as the most common genotype, 
suggesting that high TNF levels may be associated with the progression to malignancy. 
However, as neither population differed significantly to the control population, it does 
suggest that this locus does not play an important role in the control of TNF or LT 
production in relation to malignancy.
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At the AspH-1 locus the genotype expression patterns of the malignant populations is 
more site-specific. (The choice of adenocarcinoma groups allows site-specificity to be 
tested because the other two populations develop tumours in the gastro-intestinal tract 
whereas the breast cancer group tend to develop them in the bones). Both the gastric 
and colorectal groups most frequently express (2 ,2) whereas in the breast cancer group,
(1,2) is most common. However, taken across the three genotypes, no malignant 
population differs significantly to the controls. The results again suggest that the locus 
does not play any role in the progression to malignancy through the control of TNF or 
LT due to the overall similarities to the control population.
At the TNFc locus,there is an overexpression of allele 2 in the breast cancer population 
although the population does not differ significantly to the controls (chisquare=5.252, 
p=0.0724). The colorectal cancer population however, differs significantly to the 
controls (chisquaie=7.395, p=0.0248) due to the same overexpression of allele 2 (data 
from Miss. H.H. Oh).The c2 homozygous genotype is associated with high TNF 
expression (Pociot et al, 1993). Furthermore, studies by Mallmann et al and Miles et al 
both showed that increased TNF levels were found in breast cancer patients with poorer 
prognoses. Taking these two facts together, the TNFc locus may be one of the 
controlling factors in TNF expression and this increased level may play a role in the 
progression to malignancy.
Some clinical data was obtained on most of the breast cancer patients. The subjects 
were divided according to whether they were node positive or node negative, with 
posidvity being taken as an indicator of poor prognosis. It was found that none of the 
node positive patients were homozygous for allele 2 at the TNFc locus whereas 7 out of 
31 node negative patients were c2 homozygotes. With reference to Pociot's data, these 
results are in contradiction of what would have been expected again suggesting that 
looking only at activated monocytes does not reflect the in vivo situation. Our data for 
the TNFc locus suggests that this locus alone is not the controlling factor in malignancy 
progression. (The differences in allelotype and genotype expression at the TNFc locus 
between the node positive and node negative patients were both statistically significant 
(p=0.0186 and 0.0401 respectively). As TNF levels were not measured in this study, 
there was no confirmation that high levels necessarily correlate with the c2  homozygous 
genotype.
97
(c) Genotype linkages within Intron I.
As the three loci in intron 1 lie within 157bp of each other it was expected that they 
would be in linkage disequilibrium ie.that certain alleles would be inherited as a group, 
as in an extended genotype. This was not the case due to the number and variety of 
significant genotype linkages present in the four populations, especially between alleles 
at the Nco-1 and AspH-1 loci From this it could be concluded that the three sites are in 
fact independent of each other. Furthermore it could be postulated that there are putative 
recombination hot-spots flanking the AspH-1 locus, but within the boundaries of the 
TNFc and Nco-1 loci.
The TNFa m icrosatellite locus.
The two remaining polymorphic sites within the TNF locus are the TNFa and b 
microsatellites, which lie 3.5kb telomeric of the LTa gene.Thc TNFb locus was omitted 
from this study. Initial optimisation attempts proved unsuccessful and the fact that the 
alleles only differ by one base instead of the usual two, made the gels harder to read 
with confidence. Since the locus is linked to the TNFa site, it was decided that data 
from only one of these sites would be necessary. Furthermore, little work has 
previously been done on this locus, whereas several studies have already looked at 
TNFa linkage with TNF levels. It was therefore thought more perdnamt to concentrate 
on TNFa and omit the TNFb locus.
At the TNFa locus several interesting observations arose. Firstly an extra allele was 
detected in one of the breast cancer samples. As it appeared 2bp larger than the al3 
allele it was named al4. This naming system has to be questioned at this point. Had the 
allele been 2bp smaller than allele 1, it would have been named aO. Any more than 2bps 
less, would have given it a minus number. A more sensible system would be to base 
the allele name on the number of repeats present For example, a l has 6  repeats of the 
TC unit so would be referred to as TNFa (TC)6 (Epplen et al, 1995). Secondly, no
sample contained the allele a8 . This has previously been shown by Crouau-Roy et al, 
1993 and Nedospasov et al, 1991 although both studies used healthy populations. This 
is perhaps further confirmation of our allele calling procedure. As with the previously 
reported studies, the a2  allele is the most frequently expressed, although it is 
overexpressed in the breast cancer population. Ten of the 84 samples expressed the 
genotype (2 ,11) which may suggest linkage disequilibrium between these two alleles.
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In our control population, (2,11) was also the most frequently expressed genotype with 
7 samples expressing it. In the study of four different populations by Crouau-Roy, they 
found linkage disequilibrium at the TNFa locus between three sets of alleles; (6,11), 
(6,12) and (7,11). The second most frequent genotype in the breast population was also 
(6,11), with 8 samples expressing it.
Previous studies by Pociot etal, 1993 showed that both the a2 and a6 alleles correlate 
with TNF secretion levels in monocytes stimulated with LPS. High secretion correlated 
with the presence of a2 whereas low secretion correlated with allele a6. Contrading 
these results are the observations of Derkx e ta l (1995). They showed that the 
endotoxin-induced TNF release in whole blood (but not PBMNCs) was significantly 
lower in individuals with alleles a2, a6 and a 10 than individuals with alleles a4 and al l .  
Returning however to the results of Pociot etal, where a2 was associated with high 
TNF levels. The a2 allele was significantly overexpressed in the breast cancer 
population compared to the control samples which further fits with the hypothesis that 
there is a role for high TNF in the early progression of breast cancer, a result also 
shown by both Mallmann and Miles. Both groups found high TNF correlated with poor 
prognosis.Furthermore, as the breast cancer population differs significantly to the 
control population when all the TNFa alleles are taken into account, this suggests a role 
for the TNFa locus in the development of breast cancer.
Extended genotypes involving the Nco-1, TNFa and TNFc loci.
As already mentioned, certain alleles at the Nco-1, TNFa and TNFc loci have all 
shown linkage with TNF levels (Nco-1 B*2, TNFa2 and TNFc2 all correlate with high 
levels of TNF whereas TNFa6 is linked with low TNF secretion). A study earlier this 
year by Derkx etal, linked a2, a6 and alO to low TNF secretion and a4 and al 1 along 
with the Nco-1 genotype (B*1,B*2) to high TNF secretion. In the breast cancer 
population, the frequency of the (2,2) genotype at the TNFc locus is increased 
compared to the control population (0.123 versus 0.051). This is also seen in the 
colorectal cancer population. At the Nco-1 locus, the (1,2) frequency is higher in the 
breast cancer and gastric cancer populations compared to the controls and there is a 
large decrease in the (1,1) genotype frequency (0.54 versus 0.130), which is linked to 
decreased TNF expression. Finally, allele 2 is overexpressed at the TNFa locus in the 
breast cancer population.
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Both the Pociot and Derkx studies show that the TNF response correlates with several 
genetic markers within the TNF gene so on this basis, an extended genotype involving 
all three loci was looked for in the breast cancer population which would further 
substantiate the hypothesis that high TNF expression is involved in the aetiology of the 
malignancy.
When all those samples homozygous for TNFc2 were analysed across the Nco-1 and 
TNFa loci, the following data was obtained;
Sample TNFc Nco-1 TNFa
90010 (2,2) (2,2) (2,4)
90021 (2,2) (2,2) (2,4)
90023 (2,2) (1,2) (7,7)
90065 (2,2) (2,2) (2,4)
90069 (2,2) (2,2) (2,5)
90071 (2,2) (2,2) (2,7)
90072 (2,2) (2,2) (2,11)
90073 (2,2) (2,2) (2,2)
90074 (2,2) (2,2) (-,-)
90080 (2,2) (1,2) (2,6)
These results show that the alleles linked with high TNF expression do seem to form 
part of an extended haplotype in that the majority are not only homozygous for TNFc2, 
but also homozygous for Nco-1 B*2 and carry a TNFa2 allele. (In the control 
population, all the c2 homozygotes (only 6 out of 115) were also homozygous for the 
B*2 allele).
When looking at all those samples homozygous forTNFa2, the following data was 
obtained;
Sample TNFa Nco-1 TNFc
90013 (2,2) (1,2) (1,2)
90029 (2,2) (1,2) (1,2)
90048 (2,2) (1,1) (1,1)
90049 (2,2) (1,2) (1,2)
90073 (2,2) (2,2) (2,2)
Here the most common haplotype is (2,2), (1,2), (1,2). This evidence is interesting 
when the results from Derkx study are noted, where the heterozygous Nco-1 genotype 
associated with high TNF.
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Looking at the samples homozygous for the Nco-1 B*2 allele, 16 out of the 34 were 
heterozygous for TNFa2,1 was homozygous for TNFa2 and the remainder did not 
express a2. As for the TNFc locus of these samples, 16 were heterozygous, 10 
homozygous for allele c l and the remaining 8 homozygous for allele c2. These results 
are less suggestive of the extended haplotype between the three sites although fewer of 
the samples are homozygous for the TNF c l allele.
Taking those samples heterozygous at the Nco-1 locus, at the TNFc locus, 15 out of 42 
were heterozygous, 25 were homozygous for allele c l and 2 were homozygous for 
allele c2. As for the TNFa locus in these samples, 20 expressed allele a2, a further 19 
did not and the remainder failed to amplify.
Examining the samples homozygous for the Nco-1 allele B*l, 3 of the 5 expressed an 
a6  allele. The combination of B*l, a6  is linked to low TNF expression levels. More 
convincing of this, is the fact that 29 out of the 31 (B*2,B*2) samples did not express 
the a6 allele.
From the above data it can be concluded that several of the samples do display an 
extended genotype including the three alleles previously correlated with high TNF 
expression which further substantiates its role in the aetiology of the disease. Also, a 
second subset of samples also exists displaying a6 , B*1 which are both linked with low 
TNF expression. In the node negative patients, 8 out of 26 who carried a B*1 allele 
also carried an a6 allele. In the node positive group, 9 out of 21 with B*1 also carried 
a6 .
H L A  e x n r e s s i n n  a n d  a s s o c i a t i o n s  w i t h  T N F .
Because of the localisation of the TNF genes to within the MHC class I and class II 
genes and the biological roles of the gene products, it is worth considering the 
expression patterns of the HLA molecules in tumours and associations between these 
antigens and TNF alleles in non-immune as well as autoimmune diseases.
In most cell types, HLA class II expression is not constitutive, but can be induced by 
physiological inducers such as TNF and interferon gamma. The pattern of expression 
of these cell surface antigens changes in relation to the cells' functional capacity.
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Alterations such as de novo expression, a decrease or even complete loss of expression 
are often associated with oncogenesis and also autoimmune disease. A study in 1994 by 
Cabrera et al investigated the biological implications of HLA-DR expression in 
tumours.They found that 36% of tumours derived from HLA-DR positive normal 
breast tissue retained their ability to express the HLA molecules and moreover that there 
was a clear relationship between DR expression and tumour differentiation. Tumours 
which still expressed the HLA-DR molecules tended to be less well differentiated and 
the patients were given a better prognosis. This could perhaps be explained by the fact 
that antigen presentation at the site of the tumour will be enhanced, as consequently will 
be the immune response, leading to heightened tumour destruction. As TNF is known 
to be one of the molecules able to induce HLA-DR expression, it could be postulated 
that this is one of the roles of the higher levels of TNF seen in some cancers in patients 
given better prognoses (Mallmann et al, 1991).
An earlier study by Bendtzen et al in 1988 concentrated on the association between 
HLA-DR2 and the LPS-induced production of TNF in the mononuclear cells from
healthy individuals. They found that cells from HLA-DR2+ individuals secreted
significantly less TNF than those from HLA-DR2" individuals. This is evidence that 
TNF is influenced by genes in the HLA-DR region. This is more interesting when it 
was shown that there were no other correlations between TNF and other HLA 
molecules, including the HLA-B antigens. The HLA-B locus is nearer the TNF locus 
than the HLA-DR locus, so stronger linkage disequilibrium would therefore be 
expected between HLA-B and allelic variants within or in close proximity to the TNF 
gene. This is an argument against the possibility that the TNF/HLA-DR association 
involves a variant of the TNF promoter. It could however be that the HLA-DR 
molecules are involved in the release or uptake of TNF. Alternatively, regulatory genes 
located close to the HLA-DR locus are involved in the expression of the TNF gene.
As already mentioned TNF-HLA associations are involved in autoimmune diseases 
such as rheumatoid arthritis (RA) and insulin dependent diabetes mellitus (IDDM). 
HLA-DR2 is associated with resistance in these two cases and may be explained if TNF 
is involved with the destruction of cartilage and bone in RA and islet-0 cells in IDDM. 
As well as associations with single HLA loci and indeed single HLA antigens, there is 
now substantial evidence for the association of TNF alleles with ancestral haplotypes.
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Such 'ancestral haplotypes' refer to haplotypes carrying particular combinations of 
MHC alleles, which have been serologically and RFLP typed, spanning particular 
physical genomic distances. They account for between 30 and 90% of all MHC 
extended haplotypes or supratypes and consequently account for most linkage 
disequilibrium between MHC alleles. The 'extended haplotype' describes a series of 
allele combinations occurring more frequently than expected from their individual allele 
frequencies.
In 1991, Abraham et al showed that the two most common ancestral haplotypes, 57.1
and 8.1, are allelic in that they differ in their LTa sequences. They demonstrated that
57.1 carries the Nco-1 B*2 allele whereas 8.1 carries the B*1 allele. Veijans et al 
(1992) carried out further work on associations between the TNF locus and HLA 
antigens and found the Nco-1 B*1 allele to be associated with DR4 and B15, whereas 
the B*2 allele associated with the haplotype Al, B8, DR3. This latter association was 
also seen by Peruccio et al (1993). Also in 1993, Wilson et al showed that the -308 
allele T2 associated with the Al, B8, DR3 haplotype, whereas the T1 allele associated 
with DR4 and DR6 . Due to the proximity of the two genes they postulated that the 
association was a result of linkage disequilibrium.
HLA expression in Breast cancer.
Since the late 1970s, evidence has been coming to light that certain HLA antigens are 
associated with susceptibility or resistance to cancer. Rogentine et al (1977) showed an 
association with the presence of HLA-Aw 19 and/or B5 and resistance to the 
progression of lung carcinomas in a study of 70 cancer patients. This positive 
association was also found in 1979 by Weiss et al who showed that 50% of lung 
cancer patients who survived for at least one year carried these antigens. In 1977, 
Oliver et al demonstrated that acute myeloid leukaemia patients expressing Aland B8 
and/or A2 and B12 survived longer than patients without either of these pairs of 
antigens in association. In direct contrast to this, Tongio et al (1981) showed that B12 
is overexpressed in lung cancer patients and concluded that this increase is associated 
with susceptibility to the disease rather than resistance to it. Further studies noting an 
association with HLA antigens and disease susceptibility include Osoba et al (1980) 
who observed significantly poorer survival rates in Hodgkin's lymphoma patients who 
expressed Awl9 and Markman et al (1984) who found that small cell lung carcinoma 
patients possessing Al had a significantly poorer 1-year survival rate.
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We were unable to carry out HLA-typing of the 88 breast cancer samples obtained for 
this study. Furthermore, there seems to be a general lack of up-to-date data available on 
this front. However, a study was recently carried out in India by Biswal et al (1994), 
where 100 female patients with invasive breast carcinomas were analysed for HLA 
class I expression, as an approach to show a genetic correlation in this familial disease.
At the HLA-A locus two antigens, A2 and Al 1 displayed an increased frequency of 
expression in the breast cancer population when compared to aged matched controls 
(p=0.02 and 0.005 respectively). The group were also able to demonstrate an increased 
expression of A2  and Aw31 in patients whose lymphocyte cytotoxicity test results were 
high.
The results at the HLA-B locus obtained in this Indian study do not appear similar to 
work previously done. An early study by Lynch et al (1977) reported an increased 
frequency of B15, B35 and B40 in breast cancer. Hammond et al (1979) found B52 to 
be increased, while Garam et al (1980) showed a significant decrease in B14 
expression. Biswal et al however found HLA-B8 and B14 to be increased to 
statistically significant levels (p= 0.0046 and 0.005) respectively. The variations in 
findings could be due to the vast heterozygosity observed at the HLA-B locus, which 
would be even more striking when different ethnic populations and geographic 
locations are studied. Biswal's results at this locus link with work done by Jongeneel et 
al (1991), who investigated extended haplotypes. They found HLA-B8 to be 
associated with the TNFa2 allele. This may suggest that other markers within the MHC 
locus could also be linked to the control of TNF secretion levels.
Only one antigen at the HLA-C locus showed an association with breast cancer. Cw6 
appeared to be negatively associated (p=0.05). Song et al (1989) reported a positive 
association with Cw4.
A study by Concha et al, (1991) investigated whether the HLA class I phenotype could 
be used as a prognostic indicator in patients with breast carcinomas. They observed that 
39% of patient tumours showed selective or complete loss of HLA class I molecules. 
This negative phenotype was associated with the increased presence of metastases and 
short survival time. It is unclear however whether the loss of HLA expression is due to 
immune selection or a secondary event occuring during tumour progression.
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The overall variations in the association of HLA-A, B and C antigens and breast cancer 
seem to suggest the presence of susceptibility genes located within or in close proximity 
to the MHC locus. Interesting is Biswal's finding that B8 is increased in the breast 
cancer population, since B8 is part of the extended haplotype (Al, B8, DR3) which 
also associates with the Nco-1 B*2 allele, linked to increased TNF expression. This 
could be further evidence for the role of high TNF levels in the malignancy.
As far as class II expression is concerned, in 1994, Sheen-Chen investigated the 
prognostic significance of HLA-DR expression in node-negative breast cancer patients. 
Planning post-operative treatment for this group of patients is difficult It would be 
unfortunate to subject patients to unnecessary, toxic and expensive adjuvant treatments 
if their prognosis following surgery alone was good enough that it merited no further 
treatment. Sheen-Chen et al, in an attempt to identify such patients, showed that the 5- 
year disease-free survival rate of DR+ patients was significantly greater than DR- 
patients. The overall survival rate in the DR+ group was also greater, but not 
significantly so. When the combination of HLA-DR expression and oestrogen receptor 
status was used, both the 5-year and the overall survival rates of patients staining 
positive for both were significantly better than patients staining negative for both. From 
this study, it could be concluded that HLA-DR expression may be a predictive factor to 
node-negative breast cancer, especially when taken together with oestrogen receptor 
expression. Remembering that TNF can induce HLA-DR expression, this may be 
further evidence that it is TNF levels in these patients which is involved in the better 
prognosis.
The role of high TNF levels in cancer.
There is conflicting information regarding the role of high TNF levels in cancer 
patients. In this study, there seems to be an overall trend towards an increased 
expression of TNF alleles associated with elevated TNF levels, although it was not 
possible to measure actual TNF levels in the samples to confirm this.
The question then arises of the role that these suggested higher levels of TNF play in 
the cancer populations. It would fall into two opposing categories;
1) Potentiating the disease.
2) Protecting from metastases once the disease has initially developed.
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Evidence for the former suggestion comes from such studies as those by Bertolini et al
(1986) who showed that TNF and LT stimulate bone resorption and inhibition of bone 
formation. Coupling this with the fact that TNF and LT have been detected in breast 
stromal cells (Miles et al, 1992) and also that IL-1 synergises with TNF and LT
(Stashenko et al, 1987), TGF-a (Lorenzo et al, 1988) and Parathyroid hormone-related 
peptide (PTHrP) (Sato et al, 1989) in bone resorption assays, is evidence for a role for 
TNF and LT in the formation of bone metastases (Figure 18). This is especially 
pertanent to breast cancer, as the first sites of metastases tend to be the bones.
As already mentioned TNF has been implicated in the upregulation of tumour 
angiogenesis (Frater-Schroder et al, 1987) and the induction of metalloproteinases, the 
latter property leading to increased tumour cell motility and invasive potential.
On the other hand, TNF also has the ability to induce other cytokines and attract 
lymphocytes to the site of the tumour, thus potentiating an immune response against the 
tumour. HLA class II expression has been increased in several tumour cells (Cabrera et 
al, 1995). This expression allows the cells to present antigens, thus reducing the degree 
of tumour aggressiveness. Obviously the more TNF present, the greater the class II 
induction leading potentially to a better prognosis (Figure 19).
It would seem however that the negative roles of TNF at the site of a tumour outweigh 
the positive effects, thus supporting the hypothesis that high levels of TNF, suggested 
by the presence of alleles linked to higher levels, in breast cancer patients associates 
with poor prognosis.
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TNF as a therapeutic strategy.
Despite having such a variety of effects on a wide range of cells, TNF has been 
investigated as a cancer therapy. Ever since the very early work by Coley and his 
'mixed toxins' showed antitumour activity in animals, attempts have been made to 
dulpicate this property in humans. Unfortunately clinical trials using TNF as a single 
agent have not met with much success. Several reasons for this failure have been 
postulated. Firsdy, the relative amount of TNF required to cause toxicity in humans is 
less than in mice ( 8-10mg/kg compared to 400mg/kg). This could prevent therapeutic 
dose levels being reached before treatment with the cytokine is stopped. Secondly TNF 
has a short half-life in vivo of 20 minutes, which could reduce the response generated. 
Thirdly, the original 'mixed toxins' probably produced many cytokines, not just TNF 
and it was the combination effect that caused the tumour regression. (Studies to date 
have been more successful when TNF is given in combination with other cytokines or 
therapeutic agents) (see later). Finally, the involvement of the immune system is an 
important factor in the production of an anti-tumour response and this may differ 
between the human and animal models. Certainly a better response is seen against 
immunogenic tumours (murine) compared with non-immunogenic tumours (human).
Several phase I and a few phase II trials have been carried out using TNF as a single 
agent in the treatment of cancer. The former aim to determine the dose which can be 
tolerated before toxicity becomes too great and also the pharmacokinetics of TNF.
Phase II trials are concerned with determining the effectiveness of a drug, or in this 
case, TNF. The results of the phase I trials demonstrated that the maximum tolerated
dose is 200pg/m2 (Spriggs and Yates, 1992), the serum half-life is 20 minutes and that 
the dose-limiting side effect is hypotension. The phase II trials where TNF has been 
given alone have been disappointing. In summarising the results of several trials, no 
more than 1% of patients showed complete tumour regression.
Phase I trials where TNF is given in combination with other cytokines or antitumour 
drugs have had greater success. If administered with INF-y, the toxicity of TNF can be 
increased by as much as 10-fold and the maximum tolerated dose decreased by 2 to 5 
fold. A phase II study by Lienard et al (1992) has shown the triple combination of 
TNF, INF-y and the alkylating agent Melphalan to be successful in the treatment of 
metastatic melanoma and sarcoma patients, with 19 out of 23 patients showing complete 
regression of their tumours.
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From these limited studies, the potential is there to develop TNF and LT as a possible 
anticancer therapy. Several new approaches are now being attempted in order to 
overcome the various problems which, up until now, have limited progress in this field. 
To increase the TNF concentration at the site of the tumour, local treatment rather than 
systemic is being attempted; Rosenberg et al (1992) developed a method of gene 
therapy where TIL cells were transduced with the TNF gene so that on infiltration, large 
doses of TNF were delivered to the tumour. Making TNF fusion proteins would be 
another strategy for targetting TNF to the site of the tumour. TNF analogues are yet 
another possibility for a therapeutic strategy, where the toxicity of the cytokine is 
decreased but the antitumour effects are not compromised. A further angle of approach 
is to increase the short half-life shown by TNF in vivo. The attachment of polyethylene 
glycol (PEG) to proteins has been shown to increase half-life (Davis et al, 1981) so 
provided that this modification would not decrease the antitumour effects, then it is 
another possible strategy.
It must be borne in mind however that increasing the TNF dose at the site of the tumour 
may in fact potentiate the metastatic process, if the treatment fails, so a balance needs to 
be achieved where enough is given to be of therapeutic use, but not too much is 
administered to counterbalance this. With insights constantly being gained into the 
mechanisms of action of TNF and also LT, pharmaceutical drug design to prevent cell 
injury and conversly, how best to use TNF therapeutically should not be too far away.
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Concluding remarks.
Several points can be concluded from the work undertaken for this project.
Firstly is the fact that allelotyping at the polymorphic sites within the TNF locus is 
possible by employing the optimised PCR-based techniques determined here. Secondly 
is the large degree of heterogeneity observed within the study populations at the TNF 
locus. However despite this heterogeneity, allelotype expression at the polymorphic 
sites seldom differs significantly between the control and malignant populations.The 
breast and colorectal cancer populations differed at the TNFc locus. The breast cancer 
population alone differed in allelotype expression at the TNFa locus (p=0.023). 
Genotype expression failed to show a malignant-specific pattern, with only the 
colorectal population differing significantly to the control population at the TNFc locus. 
(The breast cancer population only narrowly failed to differ significantly to the control 
population (p=0.0724)) at this locus. This would seem to suggest a lack of involvement 
of the TNF locus in the progression of the malignancies investigated. Previous studies 
linked the expression of certain alleles and genotypes within the locus to increased 
TNF-expression levels. In this study we have observed a significantly increased 
expression of two of these alleles (c2 and a2) and one of the genotypes (Nco-1 
heterozygosity) in the breast cancer population. Although we were unable to measure 
the actual TNF levels in our samples due to time constraints, we can suggest that the 
predicted higher levels of TNF in the breast cancer population could be a contributing 
factor in the aetiology of the disease, bearing in mind the previously observed roles of 
TNF in metastatic progression. TNF reportedly also shows anti-tumour activity, so 
provided the dosage was optimised, the potential is there to use this multifunctional 
cytokine in the treatment of malignant diseases, which conversly enough it may play a 
role in advancing.
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